Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-06.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 NF-κB-Mediated Regulation of Osteoclastogenesis
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Endocrinol Metab > Volume 30(1); 2015 > Article
Review Article
NF-κB-Mediated Regulation of Osteoclastogenesis
Brendan F. Boyce, Yan Xiu, Jinbo Li, Lianping Xing, Zhenqiang Yao
Endocrinology and Metabolism 2015;30(1):35-44.
DOI: https://doi.org/10.3803/EnM.2015.30.1.35
Published online: March 27, 2015

Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Corresponding author: Brendan F. Boyce. Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA. Tel: +1-585-275-5837, Fax: +1-585-273-3637, Brendan_Boyce@urmc.rochester.edu

Copyright © 2015 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 8,186 Views
  • 144 Download
  • 231 Web of Science
  • 224 Crossref
  • 241 Scopus
  • Osteoclasts are multinucleated cells formed mainly on bone surfaces in response to cytokines by fusion of bone marrow-derived myeloid lineage precursors that circulate in the blood. Major advances in understanding of the molecular mechanisms regulating osteoclast formation and functions have been made in the past 20 years since the discovery that their formation requires nuclear factor-kappa B (NF-κB) signaling and that this is activated in response to the essential osteoclastogenic cytokine, receptor activator of NF-κB ligand (RANKL), which also controls osteoclast activation to resorb (degrade) bone. These studies have revealed that RANKL and some pro-inflammatory cytokines, including tumor necrosis factor, activate NF-κB and downstream signaling, including c-Fos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), and inhibition of repressors of NFATc1 signaling, to positively regulate osteoclast formation and functions. However, these cytokines also activate NF-κB signaling that can limit osteoclast formation through the NF-κB signaling proteins, TRAF3 and p100, and the suppressors of c-Fos/NFATc1 signaling, IRF8, and RBP-J. This paper reviews current understanding of how NF-κB signaling is involved in the positive and negative regulation of cytokine-mediated osteoclast formation and activation.
Osteoclasts (OCs) are multinucleated myeloid lineage cells that form by cytoplasmic fusion of precursors that are formed in the bone marrow from myeloid lineage cells and circulate in the bloodstream [1]. These osteoclast precursors (OCPs) are attracted to sites on bone surfaces destined for degradation (resorption) in response to signals coming from these sites. These signals include receptor activator of nuclear factor-kappa B (NF-κB) ligand (RANKL), a multifunctional cytokine, which is expressed by a variety of cells in bone and bone marrow, including osteocytes, which are embedded in the calcified bone matrix, bone marrow stromal cells, and B and T lymphocytes [1]. Bone is continually being remodeled in the growing and adult skeleton in response to mechanical and other stimuli and to remove microscopic foci of damaged or effete bone. There are more than 1 million of these microscopic remodeling sites in the normal adult skeleton and the number increases in conditions in which OC formation is increased, such as sex-steroid deficiency, inflammatory bone disease, and hyperparathyroidism. In the first two of these conditions expression levels of pro-inflammatory cytokines, including tumor necrosis factor (TNF), interleukin-1 (IL-1) and IL-6 are increased and these, like parathyroid hormone (PTH), increase expression of RANKL to drive the increased osteoclastogenesis and activity [1]. RANKL interaction with its receptor, RANK, activates NF-κB signaling in OCPs and in OCs, which secrete protons, chloride ions, and collagenases from under the specialized ruffled portion of their cell membrane that faces the bone surface to be resorbed. Hydrochloric acid forms under this ruffled border membrane and dissolves the mineral component of the bone and cathepsin K is secreted to degrade the matrix [1]. OCs move along the bone surfaces in packs enlarging the resorption lacunae as they progress until the resorption process has been completed. Osteoblasts, the cells that form bone, are derived from mesenchymal precursors that, like OCPs, arise in the bone marrow and circulate in the blood from where they are attracted to resorption lacunae and attach to the resorbed surface and differentiate into osteoblasts. Most aspects of OC formation and activation are regulated by NF-κB signaling, which also limits OC formation induced by cytokines, including RANKL and TNF [1].
NF-κB comprises a family of transcription factors, which positively regulate the expression of many genes involved in inflammatory and other responses by binding to their promoters. They were first identified as regulators of B lymphocyte differentiation that bound to the κB site of the κ light chain gene in B cells [2,3]. Subsequent studies showed that they were involved in innate and adaptive immune responses to pathogens and autoimmune stimuli and these established their critical roles in the initiation and maintenance of inflammatory conditions. However, they also regulate many aspects of normal cellular functions [2,3], and their activity is upregulated in many common conditions, including diabetes, atherosclerosis and cancer [4]. The NF-κB family includes RelA (also known as p65), p50, p52, RelB, and c-Rel. p50 and p52 are formed from larger precursor proteins, p105, and p100, which are encoded by NF-κB1 and NF-κB2, respectively [2]. All five family members have a Rel homology domain in their N-terminus that allows them to form homo- and heterodimers with one another and to bind to specific DNA sequences on gene promoters. DNA binding requires a C-terminal transcription activation domain, which RelA, RelB, and c-Rel possess, but p50 and p52 do not, and thus they rely on interactions with these 3 other family members to positively regulate gene transcription [4]. RelA and c-Rel preferentially form heterodimers with p50, and RelA/p50 activate most of the critical signaling in the canonical pathway, which occurs soon after activation is initiated. In many publications, NF-κB or NF-κB activity refers to canonical signaling mediated by RelA/p50. In OCs and many other cells, this occurs in response to cytokines, including RANKL, TNF, and IL-1 and is transient [5]. A non-canonical NF-κB pathway is activated several hours after canonical signaling has begun by translocation of RelB/52 heterodimers to the nucleus and is sustained, lasting for many hours. This activation occurs efficiently in response to RANKL, but not to TNF [6].
NF-κB signaling comprises a number of activation steps that require ubiquitination and proteasomal degradation or processing of proteins that function as inhibitors of signaling in cells under basal/unstimulated conditions by retaining NF-κB dimers in the cytoplasm of un-stimulated cells. These inhibitory NF-κB proteins are called IκBs. They include the canonical IκBs: IκBα, IκBβ, and IκBε [7], which have multiple ankyrin repeats that allow them to bind to NF-κB dimers and interfere with the function of their nuclear localization signals. RelA/p50 heterodimers are held in an inactivate state in the cytoplasm mainly by their interaction with IκBα, but they can also bind to IκBβ. RelA:RelA homodimers and c-Rel/RelA heterodimers preferentially bind to IκBε [4]. The C-terminal portions of p105, called IκBγ, and of p100, called IκBδ, also contain multiple ankyrin repeats, which endow them with IκB-like functions [8,9]. The IκBγ portion of p105 binds to RelA and c-Rel retaining them in the cytoplasm, but it can also bind to p50 molecules in RelA/p50 heterodimers [4]. Proteasomal processing of p105 occurs constitutively in un-stimulated cells and excises the C-terminal portion to generate p50 [10]. Upon stimulation by cytokines, such as RANKL and TNF, p105 is phosphorylated and rapidly degraded in the proteasome without release of p50. In addition, IκBα, which binds to RelA/p50 heterodimers, is degraded and this allows existing p50/RelA protein heterodimers to go to the nucleus. p100 also functions as an inhibitory protein in unstimulated cells when it is bound to RelB. Non-canonical NF-κB signaling leads to ubiquitination of p100, but instead of being degraded in the proteasome, it is processed to p52 and the resulting RelB:p52 heterodimers translocate to the nucleus. Interestingly, RelB also can function as an IκB and can bind to RelA to prevent it from activating canonical signaling [11].
Canonical signaling is activated by a trimeric IκB kinase (IKK) complex, which consists of two catalytic subunits (IKKα and IKKβ) and a regulatory subunit, IKKγ, also called NF-κB essential modulator (NEMO) [4,12]. This IKK complex phosphorylates IκBα, leading to its polyubiquitination and degradation by the 26S proteasome and this is followed by translocation of RelA:p50 dimers to the nucleus (Fig. 1) [4]. Most of the IKK activity in the canonical pathway in cells, including RANKL-induced signaling in OC precursors, is mediated by IKKβ. Two important additional inhibitory effects of canonical IKK signaling are that it up-regulates: (1) early expression of IκBα, which initiates a negative feedback loop and limits subsequent RelA/p50 translocation [13]; and (2) p100 expression later to limit signaling in the non-canonical pathway [6]. As will be seen later, p100 has important inhibitory effects to limit RANKL- and TNF-induced osteoclastogenesis [14].
Non-canonical signaling is activated by IKKα following its phosphorylation by NF-κB-inducing kinase (NIK). In unstimulated cells, NIK is constitutively ubiquitinated on receptors, such as CD40, by TNF receptor-associated factor 3 (TRAF3) in a complex that includes TRAF2 and the inhibitor of apoptosis (IAP) proteins, cellular IAP 1 (cIAP1) and 2 [15]. Following stimulation by CD40 ligand in B cells, for example, cIAP1/2 ubiquitinate TRAF3, leading to its degradation and release of NIK from this complex. NIK then phosphorylates IKKα resulting in processing of p100 in the proteasome to p52 and the formation of RelB:p52 heterodimers (Fig. 1) [16,17]. The IκBδ portion of p100 binds preferentially to RelB to retain it in the cytoplasm, but interestingly it also binds to and regulates RelA homodimers [18].
Recent studies indicate that canonical [19] and non-canonical [20] NF-κB signaling negatively regulates mesenchymal precursor differentiation into osteoblasts, suggesting that NF-κB inhibitors should be able to stimulate bone formation. In addition, NF-κB is involved in certain aspects of endochondral ossification during skeletogenesis [21], but these aspects of NF-κB functions are beyond the scope of this review.
A role for NF-κB in bone cells was first discovered unexpectedly in the mid-1990s when two groups of investigators generated NF-κB1/2 double knockout (dKO) mice in studies to further investigate the role of NF-κB in immunity and immune responses. They had already identified modest immune deficiencies in mice lacking NF-κB 1 or 2, RelB or c-Rel, while p65-/- mice died during embryogenesis from overwhelming TNF-induced liver cell apoptosis [22]. These dKO mice had failure of tooth eruption and osteopetrosis because they did not form OCs [23,24], but they also had severe B cell and T cell differentiation defects and did not form lymph nodes [23,24]. The osteopetrosis and immune deficiencies were reversed in the mice by transplantation of hematopoietic cells from wild type (WT) mice, indicating that the defects were of hematopoietic and not of mesenchymal cell origin [23]. The above OC, immune cell and lymph node formation defects were found also in RANKL and RANK knockout (KO) mice [5], which were generated a short time later independent of these studies. RANKL and RANK were discovered also largely unexpectedly by other investigators [25,26,27]. Although the NF-κB dKO and RANKL KO mice fail to form OCs, they have increased numbers of RANK-positive, TRAP-, cathepsin K-, and the calcitonin receptor-negative OCPs in their spleens [28]. These findings indicate that NF-κB signaling downstream of RANKL is not necessary for differentiation of myeloid cells into OCPs, but that it is required for terminal differentiation of these RANK-positive cells. Cytokines, including TNF, IL-1, IL-6, and RANKL did not rescue the defect in dKO OCP differentiation, indicating that NF-κB plays a central role in cytokine-induced OC formation [29]. Expression of RANK is promoted in myeloid precursors by macrophage-colony stimulating factor, which like RANKL is required for OC formation and regulates many aspects of OC formation and survival [30,31,32]. During RANKL-mediated osteoclastogenesis, RANK expression is transiently down-regulated by the β2 integrin, CD11b, to limit OC formation [33] during the earliest stages of OC formation.
NF-κB p100-/- and p105-/- mice have normal OC numbers and function in vivo, and IL-1 induces similar numbers of OCs from OCPs from these mice as it does from WT mice [29], indicating that neither is required for basal or IL-1-induced OC formation. RelA-/- mice die early during embryogenesis due to TNF-mediated massive hepatocyte apoptosis [22], but mice generated with deficiency of RelA only in hematopoietic cells have a defective response to RANKL in vivo [34]. Furthermore, inhibition of RelA nuclear translocation in OCPs in vitro inhibits osteoclastogenesis [34]. RelB-/- mice have near normal numbers of OCs, but their OCPs have an impaired response to RANKL in vitro [35]. No bone phenotypes have been reported in c-Rel-/- mice, and OCPs from these mice form normal numbers of OCs in response to RANKL in vitro [36].
Canonical NF-κB signaling is induced rapidly in OCPs in response to RANKL. For example, within an hour there is a rapid and transient increase in RelA and p50 mRNA expression levels [37]. During this period, RelA and p50 along with nuclear factor of activated T cells 2 (NFATc2; which, unlike NFATc1, is not required for OC formation) are recruited to the promoter of NFATc1, which has been called the master regulator of osteoclastogenesis, and this induces transient auto-amplification of NFATc1 expression [38]. The major role of NFATc1 at this very early stage of osteoclastogenesis may be to down-regulate expression of constitutively active repressors of RANK signaling [39], rather than induce expression of osteoclastogenic genes. These include Bcl6, which binds to the NFATc1 promoter in unstimulated OCPs and thus inhibits osteoclastogenesis. Bcl6 recruitment to the NFATc1 gene promoter is induced by CD11b during the early stages of osteoclastogenesis [33], and upon RANKL stimulation Bcl6 is replaced by NFATc1 to facilitate NFATc1 auto-amplification.
Interferon regulatory factor-8 (IRF8), Eos, and v-maf musculoaponeurotic fibrosarcoma oncogene family protein B are additional constitutively-expressed transcriptional repressors of RANK signaling in OCPs [39]. As will be seen later, negative regulation of signaling pathways in response to osteoclastogenic cytokines can play significant roles to limit OC formation and bone loss. The major role of RelA in OC formation is to prevent RANKL-induced OCP apoptosis, which is mediated by JNK, Bid and caspase 3 [34]. It remains to be determined how or if this is linked to the down-regulation of repressors of RANK signaling.
Following the transient increase in NFATc1 expression, c-Fos and p52 levels increase in OCPs ~2 hours after RANKL treatment and these remain increased thereafter through the later stages of osteoclastogenesis without any further change in RelA or p50 mRNA levels [40]. NFATc1 expression levels increase again 72 to 96 hours after RANKL treatment to induce expression of DC-STAMP, cathepsin K, TRAP, and other genes involved in OC resorptive functions. This increase in NFATc1 requires c-Fos expression induced by NF-κB since over-expression of c-Fos in NF-κB dKO OCPs induces NFATc1 expression and OC formation in the absence of RANKL stimulation [40]. Bcl6 also binds to the DC-STAMP and cathepsin K promoters in unstimulated OCPs and presumably is removed from these sites to facilitate NFATc1-induced OCP fusion and OC activation [41]. It has not been established if c-Fos expression is also required for the early transient induction of NFATc1 expression or why a more sustained expression of NFATc1 is not required to keep the above mentioned constitutively active repressors of RANK signaling inactive.
RANK, like other members of the TNF receptor superfamily, lacks intrinsic kinase activity to mediate downstream signaling [42]. In response to RANKL, RANK recruits a variety of molecules, including the multifunctional adaptor molecules, TRAFs 1, 2, 3, 5, and 6, and kinases, such as TGFβ-activated kinase-1 (TAK1), but of these only TRAF6 appears to be required for OCP differentiation in the canonical NF-κB pathway [42]. TAK1 induces activation of IKKβ leading to phosphorylation and subsequent activation of IKKβ, which phosphorylates IκB. The importance of this sequential activation process is highlighted by the observation that mice with deletion of IKKβ in OC lineage cells (IKKβf/f; CD11b-Cre [43,44] or IKKβf/f; Mx1-Cre mice [43,44]) have defective OC formation and osteopetrosis, and that OCPs from mice with a constitutively-active IKKβ (IKKβ-SS/EE) form OCs in the absence of RANK or RANKL treatment [45]. Expression of IKKβ, but not IKKα, is required for basal osteoclastogenesis and OC survival [43,44], and administration of a NEMO-binding domain peppeptide, which inhibits IKKβ activation, prevents OC formation and joint inflammation and erosion in mice with inflammatory arthritis [46]. Furthermore, macrophages, OCPs and immune cells deficient in IKKβ undergo apoptosis in response to TNF, an effect that is mediated by activation of JNK signaling [43,44]. Thus, increased IKKβ signaling mediates both joint inflammation and erosion in inflammatory arthritis.
Several studies have reported that NIK-/-, p100-/-, and RelB-/- mice have normal numbers of OCs and no or minimal osteopetrosis in vivo [23,29,35,47], indicating that non-canonical signaling is not be required for basal OC formation. IKKα functions downstream of NIK in the non-canonical pathway, and it is not surprising therefore that IKKα-/- mice have normal OC numbers and bone volume. OCPs from IKKα-/- mice, similar to those from NIK-/- mice, do not form OCs in response to RANKL in vitro [47], but interestingly they form OCs in response to TNF or IL-1 [44]. In addition, mice lacking either NF-κB2 [23] or RelB [35] and NF-κB2/RelB dKO mice that we generated [48] have normal OC formation and bone volume in vivo. However, TNF induced similar numbers of OCs as RANKL from NF-κB2-/- OCPs [14], and RANKL induced fewer OCs from RelB-/- OCPs in vitro than from WT cells [35]. In addition, bone loss induced by cancer cells injected into tibiae of RelB-/- mice was significantly less than in WT mice [35], and overexpression of RelB can rescue the defect in OC formation from NIK-/- OCPs [49]. These findings suggest that non-canonical signaling mediated by NIK and RelB is required for the increased osteoclastogenesis induced by metastatic cancer in bone and in inflammatory arthritis. In contrast, we found that RelB-/- mice responded similarly to WT littermates and generated large numbers of OCs, associated with marked bone loss in response to daily injections of RANKL (unpublished observation). Metastatic cancers and inflamed joints produce a variety of factors in addition to RANKL, some of which can inhibit OC formation. In particular, RelB-/- mice have increased expression levels of several inflammatory cytokines and develop multiorgan inflammation as they age [50,51], indicting that the inflammatory milieu in the bone marrow of these mice is abnormal. Thus, the discrepancy between our findings with RANKL inducing brisk OC formation in the RelB-/- mice and these findings might reflect differences in the balance between stimulators and inhibitors of OC formation in the bone marrow microenvironment of RelB-/- mice with metastatic tumors or inflammatory arthritis.
Non-canonical NF-κB signaling is negatively regulated by TRAF3, and the CD40L-mediated degradation of TRAF3 by TRAF2/cIAP1/2 in the non-canonical pathway described above in B cells also occurs in OCPs in response to RANKL [14,52]. This results in NIK-mediated proteasomal degradation of p100 and p52/RelB nuclear translocation. TRAF3 is typically degraded in B cells through the ubiquitin-proteasome pathway by E3 ubiquitin ligases, such as Peli1 [53] and Triad3A [54], while deubiquitinases, such as OTUD7B, inhibit TRAF3 proteolysis and limit aberrant non-canonical NF-κB activation [55]. However, in OCPs, TRAF3 degradation occurs by autophagosomal, rather than proteasomal, degradation and its degradation is prevented in vitro by chloroquine [52], which raises the pH in lysosomes and thus inhibits lysosomal enzymes that function in acidic conditions [56].
Chloroquine has been used for many decades to treat malaria, and it and hydroxychloroquine are used also to dampen immune responses in inflammatory diseases, including rheumatoid arthritis and lupus erythematosis [57,58]. By preventing TRAF3 degradation, chloroquine dose-dependently inhibited RANKL-induced OC formation in vitro and prevented PTH-induced bone resorption and ovariectomy (OVX)-induced bone loss in mice in vivo [52]. TRAF3-/- mice die within the first week or two after birth with multiorgan inflammation associated with uncontrolled NIK activity, which is rescued by crossing the mice with p100-/- mice [59], consistent with p100 acting as a negative regulator of inflammatory signaling in the non-canonical pathway. This early lethality limits their use in study of the role of TRAF3 in OC formation and bone remodeling with age. To circumvent this hurdle, we generated mice with TRAF3 conditionally deleted in OC lineage cells and found that the mice developed osteoporosis as they aged as a result of increased OC formation and bone resorption [52], providing further evidence that TRAF3 functions as a major negative regulator of OC formation. These studies suggest that chloroquine could be administered to humans to prevent age- and sex steroid deficiency-related osteoporosis. However, chloroquine has a number of side-effects, which could limit its use in postmenopausal osteoporosis unless it could be targeted to bone.
RANKL and TNF activate NF-κB, c-Fos and NFATc1 sequentially in vitro in OCPs in a very similar manner [5,14,40], but TNF induces significantly fewer OCs in vitro than RANKL from WT OCPs [40]. TNF induces similar numbers of OCs from RANK-/- and WT OCPs in vitro, but it does not induce OC formation when administered to RANK-/- mice in vivo [27], suggesting that it induces one or more inhibitors of osteoclastogenesis. TNF and RANKL induce expression of the inhibitory NF-κB p100 protein [6], which is processed efficiently to p52 by RANKL, but not by TNF [60]. We found that TNF and RANKL induced similar numbers of OCs from p100-/- OCPs in vitro [14] and that TNF induced the formation of numerous OCs in p100/RANK dKO and p100/RANKL dKO mice in vivo, indicating that TNF can induce OC formation in the absence of RANKL signaling when this inhibitory protein is also absent [14]. Furthermore, TNF-transgenic mice lacking p100 developed more severe joint erosion and inflammation than TNF-Tg mice, providing evidence that p100 limits not only TNF-induced osteoclastogenesis, but also inflammation [14]. The importance of non-canonical signaling in TNF-induced inflammatory arthritis is further supported by the finding that NIK-/- mice have decreased joint inflammation in a model of TNF-induced arthritis [47]. These studies suggest that strategies to increase TRAF3 or p100 levels in OCPs and inflammatory cells should reduce joint inflammation and erosion in patients with TNF-mediated inflammatory arthritis.
Zhao et al. [39] have identified other TNF- and RANKL-induced inhibitors of OC formation. These include IRF8, which as mentioned earlier constitutively represses RANK signaling by inhibiting the expression and function of NFATc1 [61]. IRF8-/- mice have severe osteoporosis due to increased OC numbers and function, and OCPs from the mice form more OCs in response to TNF and RANKL than WT cells [61]. Recent studies report that IRF8 expression is down regulated epigenetically during RANKL-induced osteoclastogenesis through its DNA methylation by DNA methyltransferase 3a (Dnmt3a) [62]. These investigators found that RANKL induces a metabolic shift towards oxidative metabolism during osteoclastogenesis, accompanied by increased production of S-adenosylmethionine (SAM) a methyl donor in the methylation reaction, and that SAM-mediated DNA methylation of IRS8 by Dnmt3a represses expression of this anti-osteoclastogenic gene.
Another inhibitor of OC formation is recombination signal binding protein for immunoglobulin kappa J region (RBP-J) [63], which is the major transcriptional activator of Notch signaling. RBP-J suppresses induction of NFATc1 by dampening activation of c-Fos and suppressing induction of B lymphocyte-induced maturation protein-1 (BLIMP1) [63]. By these mechanisms, it prevents downregulation of IRF8 to maintain blockage of OCP differentiation. Mice deficient in RBP-J were protected from TNF-induced bone resorption and inflammatory bone destruction. In addition RBP-J expression is responsible in part at least for the osteopetrotic phenotypes in mice lacking either DAP12 or DAP12 and FcRγ [64] because the phenotype was largely rescued when these mice were crossed with RBP-J-/- mice and TNF was able to induce OC formation and bone resorption in DAP12-/- mice. RBP-J suppresses induction of NFATc1, BLIMP1, and c-Fos by inhibiting immunoreceptor tyrosine-based activation motif (ITAM)-mediated expression and function of PLCγ2 and activation of downstream calcium-CaMKK/PYK2 signaling. DAP12 and FcRγ mediate co-stimulatory signaling-induced OC formation downstream of ITAM. These important findings indicate that RBP-J suppresses ITAM-mediated co-stimulatory signaling and in this way limits crosstalk between ITAM and RANK/TNF receptors signaling. They highlight the complexity of inflammation-induced OC formation and activation and fine-tuning of osteoclastogenesis that is required during bone homeostasis and in inflammatory bone diseases.
Acknowledgements
Some of the research described in the paper was supported by grants from the National Institute of Health PHS awards AR043510 to BFB and AR48697 and AR63650 to LX.

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 2013;28:711–722. ArticlePubMedPMC
  • 2. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–759. ArticlePubMedPDF
  • 3. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006;25:6831–6843. ArticlePubMedPDF
  • 4. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009;27:693–733. ArticlePubMed
  • 5. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9(Suppl 1):S1ArticlePubMed
  • 6. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, Teitelbaum SL. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003;198:771–781. ArticlePubMedPMCPDF
  • 7. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344–362. ArticlePubMed
  • 8. Dobrzanski P, Ryseck RP, Bravo R. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 1995;10:1003–1007. PubMed
  • 9. Liou HC, Nolan GP, Ghosh S, Fujita T, Baltimore D. The NF-kappa B p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50. EMBO J 1992;11:3003–3009. ArticlePubMedPMC
  • 10. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773–785. ArticlePubMed
  • 11. Madge LA, May MJ. The NFkappaB paradox: RelB induces and inhibits gene expression. Cell Cycle 2011;10:6–7. ArticlePubMed
  • 12. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, Omata M. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007;179:2681–2685. ArticlePubMed
  • 13. Basak S, Behar M, Hoffmann A. Lessons from mathematically modeling the NF-kappaB pathway. Immunol Rev 2012;246:221–238. ArticlePubMedPMC
  • 14. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009;119:3024–3034. ArticlePubMedPMC
  • 15. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, Shiba T, Yang X, Yeh WC, Mak TW, Korneluk RG, Cheng G. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371–1378. ArticlePubMedPMCPDF
  • 16. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280–288. ArticlePubMed
  • 17. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappaB signaling pathway. Science 2001;293:1495–1499. ArticlePubMed
  • 18. Fusco AJ, Savinova OV, Talwar R, Kearns JD, Hoffmann A, Ghosh G. Stabilization of RelB requires multidomain interactions with p100/p52. J Biol Chem 2008;283:12324–12332. ArticlePubMedPMC
  • 19. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 2009;15:682–689. ArticlePubMedPMCPDF
  • 20. Yao Z, Li Y, Yin X, Dong Y, Xing L, Boyce BF. NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. J Bone Miner Res 2014;29:866–877. ArticlePubMedPMC
  • 21. Xing L, Chen D, Boyce BF. Mice Deficient in NF-kappaB p50 and p52 or RANK Have Defective Growth Plate Formation and Post-natal Dwarfism. Bone Res 2013;4:336–345. Article
  • 22. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995;376:167–170. ArticlePubMedPDF
  • 23. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997;11:3482–3496. ArticlePubMedPMC
  • 24. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3:1285–1289. ArticlePubMedPDF
  • 25. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176. ArticlePubMed
  • 26. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597–3602. ArticlePubMedPMC
  • 27. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000;97:1566–1571. ArticlePubMedPMC
  • 28. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002;17:1200–1210. ArticlePubMed
  • 29. Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, Boyce BF. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 2003;18:260–269. ArticlePubMed
  • 30. Fuller K, Owens JM, Jagger CJ, Wilson A, Moss R, Chambers TJ. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med 1993;178:1733–1744. ArticlePubMedPMCPDF
  • 31. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993;91:257–263. ArticlePubMedPMC
  • 32. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442–444. ArticlePubMedPDF
  • 33. Park-Min KH, Lee EY, Moskowitz NK, Lim E, Lee SK, Lorenzo JA, Huang C, Melnick AM, Purdue PE, Goldring SR, Ivashkiv LB. Negative regulation of osteoclast precursor differentiation by CD11b and beta2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res 2013;28:135–149. ArticlePubMedPMC
  • 34. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008;118:2088–2097. ArticlePubMedPMC
  • 35. Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O'Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 2008;105:3897–3902. ArticlePubMedPMC
  • 36. Novack DV. Unique personalities within the NF-kappaB family: distinct functions for p65 and RelB in the osteoclast. Adv Exp Med Biol 2011;691:163–167. ArticlePubMed
  • 37. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261–1269. ArticlePubMedPMCPDF
  • 38. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889–901. ArticlePubMed
  • 39. Zhao B, Ivashkiv LB. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther 2011;13:234ArticlePubMedPMC
  • 40. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007;282:18245–18253. ArticlePubMed
  • 41. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, Miyamoto K, Hao W, Yoshida S, Morioka H, Chiba K, Kato S, Tokuhisa T, Saitou M, Toyama Y, Suda T, Miyamoto T. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010;207:751–762. ArticlePubMedPMCPDF
  • 42. Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ. TRAFs in RANK signaling. Adv Exp Med Biol 2007;597:152–159. ArticlePubMed
  • 43. Otero JE, Dai S, Foglia D, Alhawagri M, Vacher J, Pasparakis M, Abu-Amer Y. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem 2008;283:24546–24553. ArticlePubMedPMC
  • 44. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, Karin M. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005;201:1677–1687. ArticlePubMedPMCPDF
  • 45. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y. IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res 2010;25:1282–1294. ArticlePubMedPMC
  • 46. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617–624. ArticlePubMedPDF
  • 47. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005;115:1848–1854. ArticlePubMedPMC
  • 48. Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT, Boyce BF. Noncanonical NF-kappaB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells 2012;30:709–718. ArticlePubMed
  • 49. Taniguchi R, Fukushima H, Osawa K, Maruyama T, Yasuda H, Weih F, Doi T, Maki K, Jimi E. RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF-kappaB2 processing by IKKalpha. J Biol Chem 2014;289:7349–7361. ArticlePubMedPMC
  • 50. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995;80:331–340. ArticlePubMed
  • 51. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995;373:531–536. ArticlePubMedPDF
  • 52. Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao Z, Xing L, Boyce BF. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest 2014;124:297–310. ArticlePubMed
  • 53. Xiao Y, Jin J, Chang M, Chang JH, Hu H, Zhou X, Brittain GC, Stansberg C, Torkildsen O, Wang X, Brink R, Cheng X, Sun SC. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med 2013;19:595–602. ArticlePubMedPMCPDF
  • 54. Nakhaei P, Mesplede T, Solis M, Sun Q, Zhao T, Yang L, Chuang TH, Ware CF, Lin R, Hiscott J. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog 2009;5:e1000650ArticlePubMedPMC
  • 55. Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, Xiao Y, Cheng X, Chang M, Fu YX, Zal T, Zhu C, Sun SC. OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature 2013;494:371–374. ArticlePubMedPMCPDF
  • 56. Gonzalez-Noriega A, Grubb JH, Talkad V, Sly WS. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980;85:839–852. ArticlePubMedPMCPDF
  • 57. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012;42:145–153. ArticlePubMedPDF
  • 58. Miller AV, Ranatunga SK. Immunotherapies in rheumatologic disorders. Med Clin North Am 2012;96:475–496. ArticlePubMed
  • 59. He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, Doyle SE, Dempsey PW, Cheng G. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med 2006;203:2413–2418. ArticlePubMedPMCPDF
  • 60. Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 2004;279:54841–54848. ArticlePubMed
  • 61. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 2009;15:1066–1071. ArticlePubMedPMCPDF
  • 62. Nishikawa K, Iwamoto Y, Kobayashi Y, Katsuoka F, Kawaguchi SI, Tsujita T, Nakamura T, Kato S, Yamamoto M, Takayanagi H, Ishii M. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nat Med 2015;21:281–287. ArticlePubMedPDF
  • 63. Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med 2012;209:319–334. ArticlePubMedPMCPDF
  • 64. Li S, Miller CH, Giannopoulou E, Hu X, Ivashkiv LB, Zhao B. RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis. J Clin Invest 2014;124:5057–5073. ArticlePubMedPMC
Fig. 1

Canonical and non-canonical nuclear factor-kappa B (NF-κB) signaling induced by receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor (TNF). RANKL and TNF induce canonical signaling by recruiting TNF receptor (TNFR)-associated factor 6 (TRAF6) and TRAF2/5, respectively, to their receptors to activate a complex consisting of IκB kinase (IKK)-α, IKK-β and IKK-γ (NF-κB essential modulator, NEMO), which induces phosphorylation and degradation of IκB-α and the release of p65/p50 heterodimers, which translocate to the nucleus. This induces expression of c-Fos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), two other transcription factors necessary for osteoclast precursor differentiation, as well as the inhibitory κB protein, NF-κB p100. In un-stimulated cells, p100 binds to RelB to prevent its translocation to the nucleus. RANKL induces the ubiquitination and lysosomal degradation of TRAF3 through TRAF2/cellular inhibitor of apoptosis 1/2 (cIAP1/2), releasing NF-κB-inducing kinase (NIK) to activate (phosphorylate) IKK-α, which leads to proteasomal processing of p100 to p52; RelB:p52 heterodimers then go to the nucleus to induce target gene expression. TNF does not degrade TRAF3, and thus NIK is degraded, leading to the accumulation of p100 in the cytoplasm of osteoclast precursors to limit their differentiation [3,4].

enm-30-35-g001.jpg

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Photo biomodulation of dental derived stem cells to ameliorate regenerative capacity: In vitro study
      Alaa Medhat, Medhat A. El-Zainy, Iman Fathy
      The Saudi Dental Journal.2024; 36(2): 347.     CrossRef
    • Cucumber seed polypeptides regulate RANKL-induced osteoclastogenesis through OPG/RANKL/RANK and NF-κB
      Tao Yu, Xiao Liu, Meng Jiang, Yuanyue Li, Heng Su, Ben Niu
      In Vitro Cellular & Developmental Biology - Animal.2024; 60(1): 54.     CrossRef
    • MCP‐5 suppresses osteoclast differentiation through Ccr5 upregulation
      Jung Ha Kim, Kabsun Kim, Inyoung Kim, Semun Seong, Jeong‐Tae Koh, Nacksung Kim
      Journal of Cellular Physiology.2024;[Epub]     CrossRef
    • S-nitrosoglutathione reductase-dependent p65 denitrosation promotes osteoclastogenesis by facilitating recruitment of p65 to NFATc1 promoter
      Shumin Liu, Qian Lu, Min Wang, Huilin Guo, Yiwen Wang, Jingwen Nong, Shuo Wang, Haibin Xia, Ting Xia, Huifang Sun
      Bone.2024; 181: 117036.     CrossRef
    • A Missense Variant in TP53 Could Be a Genetic Biomarker Associated with Bone Tissue Alterations
      Ricardo Usategui-Martín, Nadia Galindo-Cabello, Salvador Pastor-Idoate, José María Fernández-Gómez, Álvaro del Real, Diego Ferreño, Rebeca Lapresa, Francisco Martín-Rodriguez, José A. Riancho, Ángeles Almeida, José Luis Pérez-Castrillón
      International Journal of Molecular Sciences.2024; 25(3): 1395.     CrossRef
    • Cellular and Exosomal MicroRNAs: Emerging Clinical Relevance as Targets for Breast Cancer Diagnosis and Prognosis
      Faith Mokobi Zablon, Parth Desai, Kristen Dellinger, Shyam Aravamudhan
      Advanced Biology.2024;[Epub]     CrossRef
    • Pleurotus sajor-caju (Fr.) Singer β-1,3-Glucanoligosaccharide (Ps-GOS) Suppresses RANKL-Induced Osteoclast Differentiation and Function in Pre-Osteoclastic RAW 264.7 Cells by Inhibiting the RANK/NFκB/cFOS/NFATc1 Signalling Pathway
      Purithat Rattajak, Aratee Aroonkesorn, Carl Smythe, Rapepun Wititsuwannakul, Thanawat Pitakpornpreecha
      Molecules.2024; 29(9): 2113.     CrossRef
    • Discovery of a Potent Antiosteoporotic Drug Molecular Scaffold Derived from Angelica sinensis and Its Bioinspired Total Synthesis
      Jian Zou, Zuo-Cheng Qiu, Qiang-Qiang Yu, Jia-Ming Wu, Yong-Heng Wang, Ke-Da Shi, Yi-Fang Li, Rong-Rong He, Ling Qin, Xin-Sheng Yao, Xin-Luan Wang, Hao Gao
      ACS Central Science.2024; 10(3): 628.     CrossRef
    • Roles and mechanisms of optineurin in bone metabolism
      Junjie Jin, Ruiqi Huang, Yixing Chang, Xuejie Yi
      Biomedicine & Pharmacotherapy.2024; 172: 116258.     CrossRef
    • Therapeutic potential of a prominent dihydroxyflavanone pinocembrin for osteolytic bone disease: In vitro and in vivo evidence
      Guoju Hong, Shuqiang Li, Guanqiang Zheng, Xiaoxia Zheng, Qunzhang Zhan, Lin Zhou, Qiushi Wei, Wei He, Zhenqiu Chen
      Journal of Orthopaedic Translation.2024; 45: 197.     CrossRef
    • Hydroxychavicol Inhibits In Vitro Osteoclastogenesis via the Suppression of NF-κB Signaling Pathway
      Sirada Srihirun, Satarat Mathithiphark, Chareerut Phruksaniyom, Pitchanun Kongphanich, Wisutthaporn Inthanop, Thanaporn Sriwantana, Salunya Tancharoen, Nathawut Sibmooh, Pornpun Vivithanaporn
      Biomolecules & Therapeutics.2024; 32(2): 205.     CrossRef
    • Inhibition of NF-κB and ERK signaling pathways in osteoclasts and M1 macrophage polarization: Mechanistic insights into the anti-osteoporotic effects of Pseudolaric acid B
      Liyan Liu, Cheng Xiang, Tao Li, Ziyue Zhao, Tao Xiao, Zhengxiao Ouyang
      Life Sciences.2024; 345: 122592.     CrossRef
    • Bone equilibria and disruptions
      Harold Jacob Pieter van Bosse
      Journal of the Pediatric Orthopaedic Society of North America.2024; 7: 100059.     CrossRef
    • 6-O-angeloylplenolin inhibits osteoclastogenesis in vitro via suppressing c-Src/NF-κB/NFATc1 pathways and ameliorates bone resorption in collagen-induced arthritis mouse model
      Zhi-chao Li, Min Li, Ling-xiang Xiao, Xi Zheng, Rong Li, Shi-jia Dong, Yue Wang, Hong-yu Wen, Kun-lin Ruan, Ke-guang Cheng, Ming Chen, Yan-hui Tan
      Biochemical Pharmacology.2024; 224: 116230.     CrossRef
    • Glycogen Synthase Kinase-3 Beta (GSK3β) as a Potential Drug Target in Regulating Osteoclastogenesis: An Updated Review on Current Evidence
      Sok Kuan Wong
      Biomolecules.2024; 14(4): 502.     CrossRef
    • Expression analysis of nuclear factor kappa B (NF-κB) in oral squamous cell carcinoma
      Dev Arora, Dhanraj M. Ganapathy, Ashikha Shirin Usman Pp, K.P. Ameya, Durairaj Sekar, Kumaravel Kaliaperumal
      Oral Oncology Reports.2024; 10: 100481.     CrossRef
    • Research Progress on Inhibition of Osteoclast Differentiation by Traditional Chinese 
Medicine
      Yanan Qian, Siomui Chong, Qian Chen, Chengliang Yin, Yujing Cao
      Pharmacognosy Magazine.2024;[Epub]     CrossRef
    • RUFY4 deletion prevents pathological bone loss by blocking endo-lysosomal trafficking of osteoclasts
      Minhee Kim, Jin Hee Park, Miyeon Go, Nawon Lee, Jeongin Seo, Hana Lee, Doyong Kim, Hyunil Ha, Taesoo Kim, Myeong Seon Jeong, Suree Kim, Taesoo Kim, Han Sung Kim, Dongmin Kang, Hyunbo Shim, Soo Young Lee
      Bone Research.2024;[Epub]     CrossRef
    • IMPACT OF QUERCETIN ON THE ORGANIC MATRIX AND BIOMECHANICAL PROPERTIES OF RAT MANDIBLE FOLLOWING ITS INCOMPLETE FRACTURE DURING CHRONIC ALCOHOL INTOXICATION
      K.I. Nestulia, I.V. Ksonz, V.I. Makarenko, O.V. Makarenko, V.O. Kostenko
      Fiziolohichnyĭ zhurnal.2024; 70(3): 51.     CrossRef
    • IMPACT OF QUERCETIN ON PATHOMORPHOLOGICAL CHARACTERISTICS OF MANDIBULAR BONE IN RATS FOLLOWING ITS FRACTURE UNDER CHRONIC ALCOHOL INTOXICATION
      K.I. Nestulia, I.I. Starchenko, V.O. Kostenko
      Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2024; 24(2): 120.     CrossRef
    • HDAC5-Mediated Acetylation of p100 Suppresses Its Processing
      Jianqi Wang, Shuainan Wu, Lu Liu, Ying Pang, Zhaobao Li, Hong Mu
      International Dental Journal.2023; 73(3): 387.     CrossRef
    • HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling
      Hui-Min Cheng, Mingming Xing, Ya-Ping Zhou, Weitao Zhang, Zeyu Liu, Lan Li, Zuguo Zheng, Yuanchen Ma, Pingping Li, Xiaoxuan Liu, Ping Li, Xiaojun Xu
      Cell Death & Differentiation.2023; 30(3): 673.     CrossRef
    • Oligosaccharides from Sargassum thunbergii inhibit osteoclast differentiation via regulation of IRF-8 signaling
      Weihua Jin, Fen Chen, Qiufu Fang, Genxiang Mao, Yizhong Bao
      Experimental Gerontology.2023; 172: 112057.     CrossRef
    • ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
      Heng Qiu, Christopher Hosking, Emel Rothzerg, Ariela Samantha, Kai Chen, Vincent Kuek, Haiming Jin, Sipin Zhu, Alice Vrielink, Kevin Lim, Michael Foley, Jiake Xu
      Journal of Biological Chemistry.2023; 299(2): 102889.     CrossRef
    • In vitrobiological evaluation of epigallocatechin gallate (EGCG) release from three-dimensional printed (3DP) calcium phosphate bone scaffolds
      Yongdeok Jo, Naboneeta Sarkar, Susmita Bose
      Journal of Materials Chemistry B.2023; 11(24): 5503.     CrossRef
    • The Roles of TRAF3 in Immune Responses
      Mengjiao Lin, Xiaoli Ji, Yan Lv, Dawei Cui, Jue Xie, Dimitri Poddighe
      Disease Markers.2023; 2023: 1.     CrossRef
    • (S)-2-(Cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-κB Nuclear Translocation
      Mina Ding, Eunjin Cho, Zhihao Chen, Sang-Wook Park, Tae-Hoon Lee
      International Journal of Molecular Sciences.2023; 24(5): 4327.     CrossRef
    • Safranal inhibits estrogen-deficiency osteoporosis by targeting Sirt1 to interfere with NF-κB acetylation
      Sun-Ren Sheng, Yu-Hao Wu, Zi-Han Dai, Chen Jin, Gao-Lu He, Shu-Qing Jin, Bi-Yao Zhao, Xin Zhou, Cheng-Long Xie, Gang Zheng, Nai-Feng Tian
      Phytomedicine.2023; 114: 154739.     CrossRef
    • Discovery of PMSA Derivative 11 as a Novel Lead Compound for Therapeutic Treatment of Osteoporosis In Vitro and In Vivo
      Zhihao Chen, Karthik Rajan Rajamanickam, Mina Ding, Sang Kyoon Kim, Sang-wook Park, Eunae Kim, Sunwoo Lee, Tae-Hoon Lee
      Journal of Medicinal Chemistry.2023; 66(10): 6766.     CrossRef
    • Sesamol improves bone mass in ovary intact growing and adult rats but accelerates bone deterioration in the ovariectomized rats
      Kalpana Patel, SVVS Ravi Mangu, Shinde Vijay Sukhdeo, Kunal Sharan
      The Journal of Nutritional Biochemistry.2023; 119: 109384.     CrossRef
    • Unraveling the potential of 3D bioprinted immunomodulatory materials for regulating macrophage polarization: State-of-the-art in bone and associated tissue regeneration
      Sayan Deb Dutta, Tejal V. Patil, Keya Ganguly, Aayushi Randhawa, Ki-Taek Lim
      Bioactive Materials.2023; 28: 284.     CrossRef
    • Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα
      Alessia Oppezzo, Lovely Monney, Henri Kilian, Lofti Slimani, Frédérique Maczkowiak-Chartois, Filippo Rosselli
      Cell & Bioscience.2023;[Epub]     CrossRef
    • TMBIM6 deficiency leads to bone loss by accelerating osteoclastogenesis
      Sun-Ju Yi, You-Jee Jang, Seokchan Lee, Sung-Jin Cho, Kyuho Kang, Jae-Il Park, Han-Jung Chae, Hyung-Ryong Kim, Kyunghwan Kim
      Redox Biology.2023; 64: 102804.     CrossRef
    • The role of E3 ubiquitin ligases in bone homeostasis and related diseases
      Yuechao Dong, Yangshan Chen, Guixing Ma, Huiling Cao
      Acta Pharmaceutica Sinica B.2023; 13(10): 3963.     CrossRef
    • Bioactive silica nanoparticles target autophagy, NF-κB, and MAPK pathways to inhibit osteoclastogenesis
      Jamie Arnst, Zhaocheng Jing, Cameron Cohen, Shin-Woo Ha, Manjula Viggeswarapu, George R. Beck
      Biomaterials.2023; 301: 122238.     CrossRef
    • Comparative Study of the Cytokine Profiles of Serum and Tissues from Patients with the Ossification of the Posterior Longitudinal Ligament
      Li-Yu Fay, Chao-Hung Kuo, Hsuan-Kan Chang, Mei-Yin Yeh, Chih-Chang Chang, Chin-Chu Ko, Tsung-Hsi Tu, Yi-Hsuan Kuo, Wang-Yu Hsu, Chien-Hui Hung, Ching-Jung Chen, Jau-Ching Wu, May-Jywan Tsai, Wen-Cheng Huang, Henrich Cheng, Meng-Jen Lee
      Biomedicines.2023; 11(7): 2021.     CrossRef
    • Protaetia brevitarsis Extract Attenuates RANKL-Induced Osteoclastogenesis by Inhibiting the JNK/NF-κB/PLCγ2 Signaling Pathway
      Hye-Yeon Jang, Jeong-Mi Kim, Jong-Suk Kim, Byeong-Soo Kim, Young-Rae Lee, Jun Sang Bae
      Nutrients.2023; 15(14): 3193.     CrossRef
    • Madecassic acid suppresses osteoclast differentiation and bone resorption by inhibiting RANKL‐induced NF‐κB, JNK and NFAT signaling pathways
      Peiru Su, Xiangya Luo, Chunping Zeng, Lin Zhou
      Rheumatology & Autoimmunity.2023; 3(4): 220.     CrossRef
    • Guided Bone Regeneration Using Barrier Membrane in Dental Applications
      Kakyung Kim, Yingchao Su, Allan J. Kucine, Ke Cheng, Donghui Zhu
      ACS Biomaterials Science & Engineering.2023; 9(10): 5457.     CrossRef
    • Irisin as an agent for protecting against osteoporosis: A review of the current mechanisms and pathways
      Xinli Hu, Zheng Wang, Wei Wang, Peng Cui, Chao Kong, Xiaolong Chen, Shibao Lu
      Journal of Advanced Research.2023;[Epub]     CrossRef
    • Anti-Osteoporotic Potential of Water Extract of Anethum graveolens L. Seeds
      Seon-A Jang, Sung-Ju Lee, Youn-Hwan Hwang, Hyunil Ha
      Nutrients.2023; 15(19): 4302.     CrossRef
    • Synthesis and evaluation of 2-NMPA derivatives as potential agents for prevention of osteoporosis in vitro and in vivo
      Zhihao Chen, Devaneyan Joseph, Mina Ding, Swapnil Pandurang Bhujbal, Robin Prakash Sirvin Rajan, Eunae Kim, Sang-wook Park, Sunwoo Lee, Tae-Hoon Lee
      European Journal of Medicinal Chemistry.2023; 260: 115767.     CrossRef
    • A novel Glycyrrhiza glabra extract liquiritin targeting NFATc1 activity and ROS levels to counteract ovariectomy-induced osteoporosis and bone loss in murine model
      Guoju Hong, Lin Zhou, Guanqiang Zheng, Xiaoxia Zheng, Zhenqiu Chen, Wei He, Qiushi Wei
      Frontiers in Pharmacology.2023;[Epub]     CrossRef
    • Wearable Device for Cumulative Chlorobenzene Detection and Accessible Mitigation Strategies
      Aryan Mago, Yeon-Suk Yang, Jae-Hyuck Shim, Aijaz Ahmad John
      Sensors.2023; 23(18): 7904.     CrossRef
    • Natural drug asiaticoside inhibits osteoclast differentiation and promotes repair of steroid-induced osteonecrosis of femoral head via RANKL pathway
      Haijian Wu, Bowen Guo, Hongfa Zhong, Hui Ying
      Materials Express.2023; 13(11): 1855.     CrossRef
    • Regulating Macrophages through Immunomodulatory Biomaterials Is a Promising Strategy for Promoting Tendon-Bone Healing
      Haihan Gao, Liren Wang, Haocheng Jin, Zhiqi Lin, Ziyun Li, Yuhao Kang, Yangbao Lyu, Wenqian Dong, Yefeng Liu, Dingyi Shi, Jia Jiang, Jinzhong Zhao
      Journal of Functional Biomaterials.2022; 13(4): 243.     CrossRef
    • Trim14 promotes osteoclastogenesis and noncanonical NF‐κB activation by targeting p100/p52 in chronic periodontitis
      Jian Zhang, Xiuya Lin, Yang Sun, Jianming Wei, Jiankun Wu
      Oral Diseases.2022; 28(7): 1958.     CrossRef
    • Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications
      Tianzhong Li, Xueyan Hou, Yu Qi, Xiaohan Duan, Pengcheng Yan, Haoru Zhu, Zhongjian Xie, Han Zhang
      Nano Research.2022; 15(4): 3299.     CrossRef
    • 3D printing monetite-coated Ti-6Al-4V surface with osteoimmunomodulatory function to enhance osteogenesis
      Linquan Zhou, Jiacheng You, Zhenyu Wang, Yang Gu, Dehui Chen, Bin Lin, Xin Zhao, Jiemin Lin, Jinxin Lin, Wenge Liu
      Biomaterials Advances.2022; 134: 112562.     CrossRef
    • D(-)-salicin inhibits RANKL-induced osteoclast differentiation and function in vitro
      Yu Xiao, Yansi Xian, Xinmei Hu, Zhongquan Qi
      Fitoterapia.2022; 157: 104981.     CrossRef
    • CaP-based anti-inflammatory HIF-1α siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy
      Xuesong Liu, Ruru Guo, Shicheng Huo, Huan Chen, Qingxiang Song, Gan Jiang, Ye Yu, Jialin Huang, Shaowei Xie, Xiaoling Gao, Liangjing Lu
      Journal of Controlled Release.2022; 343: 314.     CrossRef
    • Anti-Osteoporosis Effect of Perilla frutescens Leaf Hexane Fraction through Regulating Osteoclast and Osteoblast Differentiation
      Kanokkarn Phromnoi, Supachai Yodkeeree, Komsak Pintha, Sariya Mapoung, Maitree Suttajit, Chalermpong Saenjum, Pornngarm Dejkriengkraikul
      Molecules.2022; 27(3): 824.     CrossRef
    • Biomaterial-induced pathway modulation for bone regeneration
      Steven Vermeulen, Zeinab Tahmasebi Birgani, Pamela Habibovic
      Biomaterials.2022; 283: 121431.     CrossRef
    • Proteasome inhibition-enhanced fracture repair is associated with increased mesenchymal progenitor cells in mice
      Hengwei Zhang, Xing Li, Jiatong Liu, Xi Lin, Lingpeng Pei, Brendan F. Boyce, Lianping Xing, Gianpaolo Papaccio
      PLOS ONE.2022; 17(2): e0263839.     CrossRef
    • α-Asarone Attenuates Osteoclastogenesis and Prevents Against Oestrogen-Deficiency Induced Osteoporosis
      Hao Tian, Tao Jiang, Kai Yang, Ruonan Ning, Tianqi Wang, Qi Zhou, Niandong Qian, Ping Huang, Lei Guo, Min Jiang, Xiaobing Xi, Xing Xu, Lianfu Deng
      Frontiers in Pharmacology.2022;[Epub]     CrossRef
    • Regulation of osteoclast-mediated bone resorption by microRNA
      Ling Ji, Xinyi Li, Shushu He, Song Chen
      Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef
    • Wheel-Running Exercise Protects Ovariectomized Mice from Bone Loss via IFN-γ-Mediated Suppression of the NF-κB and MAPK Pathways
      Hao Shen, Jiaheng He, Xuwei Ling, Chang Liu, Yi Wang, Xiongjinfu Zhang, Xu He, Huilin Yang, Mimi Chen, Qin Shi, Dimitrios Draganidis
      Oxidative Medicine and Cellular Longevity.2022; 2022: 1.     CrossRef
    • Transcriptomic Analysis Provides Insights to Reveal the bmp6 Function Related to the Development of Intermuscular Bones in Zebrafish
      Huan Xu, Guangxiang Tong, Ting Yan, Le Dong, Xiaoxing Yang, Dongyu Dou, Zhipeng Sun, Tianqi Liu, Xianhu Zheng, Jian Yang, Xiaowen Sun, Yi Zhou, Youyi Kuang
      Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
    • The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease
      Laetitia Marcadet, Zineb Bouredji, Anteneh Argaw, Jérôme Frenette
      Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
    • Strontium Functionalized in Biomaterials for Bone Tissue Engineering: A Prominent Role in Osteoimmunomodulation
      Jiaqian You, Yidi Zhang, Yanmin Zhou
      Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
    • Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1–Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis
      Ke Fang, Yuki Murakami, Seiji Kanda, Takaki Shimono, Anh Tuan Dang, Mitsuaki Ono, Toshimasa Nishiyama
      International Journal of Molecular Sciences.2022; 23(14): 7814.     CrossRef
    • Immunomodulation Effect of Biomaterials on Bone Formation
      Tong Zhao, Zhuangzhuang Chu, Jun Ma, Liping Ouyang
      Journal of Functional Biomaterials.2022; 13(3): 103.     CrossRef
    • Update on the pathogenesis and genetics of Paget’s disease of bone
      Luigi Gennari, Domenico Rendina, Daniela Merlotti, Guido Cavati, Christian Mingiano, Roberta Cosso, Maria Materozzi, Filippo Pirrotta, Veronica Abate, Marco Calabrese, Alberto Falchetti
      Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
    • Praeruptorin B inhibits osteoclastogenesis by targeting GSTP1 and impacting on the S-glutathionylation of IKKβ
      Kebin Xu, Ziyi Chen, Jialong Hou, Chenlin Dong, Chengge Shi, Linglin Gao, Zhixian Huang, Ge Shen, Te Wang, Yan Zhou
      Biomedicine & Pharmacotherapy.2022; 154: 113529.     CrossRef
    • How zoledronic acid improves osteoporosis by acting on osteoclasts
      Biao Wang, Yi Zhan, Liang Yan, Dingjun Hao
      Frontiers in Pharmacology.2022;[Epub]     CrossRef
    • CpG Oligodeoxynucleotides Inhibit RANKL-Induced Osteoclast Formation by Upregulating A20 Deubiquitinase in RAW 264.7 Cells
      Seong-Kyu Kim, Jung-Yoon Choe, Ki-Yeun Park, Nadra Nilsen
      Mediators of Inflammation.2022; 2022: 1.     CrossRef
    • Zuogui Pill Ameliorates Glucocorticoid-Induced Osteoporosis through ZNF702P-Based ceRNA Network: Bioinformatics Analysis and Experimental Validation
      Peng Zhang, Honglin Chen, Qi Shang, Guifeng Chen, Jiahui He, Gengyang Shen, Xiang Yu, Zhida Zhang, Wenhua Zhao, Guangye Zhu, Jinglin Huang, De Liang, Jingjing Tang, Jianchao Cui, Zhixiang Liu, Xiaobing Jiang, Hui Ren, Jun Jiang
      Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
    • Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3β Signaling
      Jinjin Cao, Ming-Xue Zhou, Xinyan Chen, Menglu Sun, Congmin Wei, Qisheng Peng, Zhou Cheng, Wanchun Sun, Hongbing Wang
      Frontiers in Immunology.2022;[Epub]     CrossRef
    • MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
      Zahra Mohtashami, Mithalesh K. Singh, Nasim Salimiaghdam, Mustafa Ozgul, M. Cristina Kenney
      International Journal of Molecular Sciences.2022; 23(19): 11991.     CrossRef
    • Topography-mediated immunomodulation in osseointegration; Ally or Enemy
      Sajjad Shirazi, Sriram Ravindran, Lyndon F. Cooper
      Biomaterials.2022; 291: 121903.     CrossRef
    • Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
      Houfu Leng, Hanlin Zhang, Linsen Li, Shuhao Zhang, Yanping Wang, Selina J. Chavda, Daria Galas-Filipowicz, Hantao Lou, Adel Ersek, Emma V. Morris, Erdinc Sezgin, Yi-Hsuan Lee, Yunsen Li, Ana Victoria Lechuga-Vieco, Mei Tian, Jian-Qing Mi, Kwee Yong, Qing
      Nature Communications.2022;[Epub]     CrossRef
    • Breaking the vicious cycle between tumor cell proliferation and bone resorption by chloroquine-loaded and bone-targeted polydopamine nanoparticles
      Yitong Wang, Hui Chen, Kaili Lin, Ting Ying, Quan Huang, Xiaopan Cai, Jianru Xiao, Qiang Zhang, Yiyun Cheng
      Science China Materials.2021; 64(2): 474.     CrossRef
    • Delineating role of NF‐κB and interacting cytokines during prostate cancer‐induced osteoclastogenesis
      Mohit Jadli, Kulbhushan Thakur, Nikita Aggarwal, Arun Chhokar, Rakhi Bibban, Tejveer Singh, Anjali Bhat, Alok C. Bharti
      Journal of Cellular Biochemistry.2021; 122(2): 259.     CrossRef
    • Dectin‐1–mediated suppression of RANKL‐induced osteoclastogenesis by glucan from baker's yeast
      Shiika Hara, Yoshie Nagai‐Yoshioka, Ryota Yamasaki, Yoshiyuki Adachi, Yuko Fujita, Kouji Watanabe, Kenshi Maki, Tatsuji Nishihara, Wataru Ariyoshi
      Journal of Cellular Physiology.2021; 236(7): 5098.     CrossRef
    • Impact of low bone mass and antiresorptive therapy on antibiotic efficacy in a rat model of orthopedic device‐related infection
      Keith Thompson, Linda Freitag, Ursula Styger, Karin Camenisch, Stephan Zeiter, Daniel Arens, R. Geoff Richards, Thomas F. Moriarty, Vincent A. Stadelmann
      Journal of Orthopaedic Research.2021; 39(2): 415.     CrossRef
    • RANKL as the master regulator of osteoclast differentiation
      Hiroshi Takayanagi
      Journal of Bone and Mineral Metabolism.2021; 39(1): 13.     CrossRef
    • Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways
      Xiong Miao, Jiabin Yuan, Jinhui Wu, Jiaoyang Zheng, Weina Zheng, Fei Wang, Chao Wang, Xiaoming Li, Shu Liu, Zhicai Shi, Jingfeng Li
      Spine.2021; 46(4): E234.     CrossRef
    • Effects of Caffeic Acid and Its Derivatives on Bone: A Systematic Review
      Sophia Ogechi Ekeuku, Kok-Lun Pang, Kok-Yong Chin
      Drug Design, Development and Therapy.2021; Volume 15: 259.     CrossRef
    • 2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fos Expression
      Zhihao Chen, Mina Ding, Eunjin Cho, Jihyoun Seong, Sunwoo Lee, Tae-Hoon Lee
      Frontiers in Pharmacology.2021;[Epub]     CrossRef
    • Dental pulp–derived stem cells inhibit osteoclast differentiation by secreting osteoprotegerin and deactivating AKT signalling in myeloid cells
      Suman Kanji, Ripon Sarkar, Asmita Pramanik, Sudhir Kshirsagar, Carl J. Greene, Hiranmoy Das
      Journal of Cellular and Molecular Medicine.2021; 25(5): 2390.     CrossRef
    • Bone anti-resorptive effects of coumarins on RANKL downstream cellular signaling: a systematic review of the literature
      Samia Jessica Silva Tavares, Vilma Lima
      Fitoterapia.2021; 150: 104842.     CrossRef
    • Isofraxidin Inhibits Receptor Activator of Nuclear Factor-κB Ligand–Induced Osteoclastogenesis in Bone Marrow–Derived Macrophages Isolated from Sprague–Dawley Rats by Regulating NF-κB/NFATc1 and Akt/NFATc1 Signaling Pathways
      Wei Wang, Bo Wang
      Cell Transplantation.2021; 30: 096368972199032.     CrossRef
    • Smac-mimetics reduce numbers and viability of human osteoclasts
      Ingrid Nyhus Moen, Marita Westhrin, Erling Håland, Markus Haug, Unni Nonstad, Merisa Klaharn, Therese Standal, Kristian K. Starheim
      Cell Death Discovery.2021;[Epub]     CrossRef
    • TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors
      Cecilia Ansalone, John Cole, Sabarinadh Chilaka, Flavia Sunzini, Shatakshi Sood, Jamie Robertson, Stefan Siebert, Iain B McInnes, Carl S Goodyear
      Annals of the Rheumatic Diseases.2021; 80(6): 748.     CrossRef
    • The role of statins in the differentiation and function of bone cells
      Sajad Chamani, Luca Liberale, Leila Mobasheri, Fabrizio Montecucco, Khalid Al‐Rasadi, Tannaz Jamialahmadi, Amirhossein Sahebkar
      European Journal of Clinical Investigation.2021;[Epub]     CrossRef
    • Biological Evaluation and Transcriptomic Analysis of Corylin as an Inhibitor of Osteoclast Differentiation
      Anna Xiao-Dan Yu, Jian Xiao, Shi-Zheng Zhao, Xiang-Peng Kong, Kenneth Kin-Leung Kwan, Brody Zhong-Yu Zheng, Kevin Qi-Yun Wu, Tina Ting-Xia Dong, Karl Wah-Keung Tsim
      International Journal of Molecular Sciences.2021; 22(7): 3540.     CrossRef
    • Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair
      Zineb Bouredji, Dounia Hamoudi, Laetitia Marcadet, Anteneh Argaw, Jérôme Frenette
      Molecular Therapy - Methods & Clinical Development.2021; 21: 559.     CrossRef
    • β-Boswellic Acid Inhibits RANKL-Induced Osteoclast Differentiation and Function by Attenuating NF-κB and Btk-PLCγ2 Signaling Pathways
      Gyeong Do Park, Yoon-Hee Cheon, So Young Eun, Chang Hoon Lee, Myeung Su Lee, Ju-Young Kim, Hae Joong Cho
      Molecules.2021; 26(9): 2665.     CrossRef
    • A novel RANKL‐targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species
      Guoju Hong, Zhenqiu Chen, Xiaorui Han, Lin Zhou, Fengxiang Pang, Rishana Wu, Yingshan Shen, Xiaoming He, Zhinan Hong, Ziqi Li, Wei He, Qiushi Wei
      Clinical and Translational Medicine.2021;[Epub]     CrossRef
    • Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis
      Chao Jiang, Qingliang Ma, Shiyu Wang, Yang Shen, An Qin, Shunwu Fan, Zhiwei Jie
      Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
    • S100 Calcium-Binding Protein P Secreted from Megakaryocytes Promotes Osteoclast Maturation
      Seung-Hoon Lee, Hye Jung Ihn, Eui Kyun Park, Jung-Eun Kim
      International Journal of Molecular Sciences.2021; 22(11): 6129.     CrossRef
    • Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
      Xue Yang, Jiamin Liang, Ziyi Wang, Yuangang Su, Yunfei Zhan, Zuoxing Wu, Jing Li, Xuedong Li, Runfeng Chen, Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou
      Frontiers in Pharmacology.2021;[Epub]     CrossRef
    • Regulation of Osteoclastogenesis and Bone Resorption by miRNAs
      Kazuki Inoue, Courtney Ng, Yuhan Xia, Baohong Zhao
      Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
    • Genomic locus proteomic screening identifies the NF-κB signaling pathway components NFκB1 and IKBKG as transcriptional regulators of Ripk3 in endothelial cells
      Siqi Gao, Matthew Menendez, Katarzyna Kurylowicz, Courtney T. Griffin, Ramani Ramchandran
      PLOS ONE.2021; 16(6): e0253519.     CrossRef
    • IL-3 inhibits rat osteoclast differentiation induced by TNF-α and other pro-osteoclastogenic cytokines
      Vikrant Piprode, Kanupriya Singh, Anil Kumar, Snehal R. Joshi, Mohan R. Wani
      Journal of Biosciences.2021;[Epub]     CrossRef
    • Water Extract of Mentha arvensis L. Attenuates Estrogen Deficiency-Induced Bone Loss by Inhibiting Osteoclast Differentiation
      Seon-A Jang, Youn-Hwan Hwang, Hyun Yang, Jin Ah Ryuk, Taesoo Kim, Hyunil Ha
      Frontiers in Pharmacology.2021;[Epub]     CrossRef
    • Exosomal tumor necrosis factor‐α from hepatocellular cancer cells (Huh‐7) promote osteoclast differentiation
      Ching‐Hao Li, Kalaiselvi Palanisamy, Xin Li, Shao‐Hua Yu, I‐Kuan Wang, Chi‐Yuan Li, Kuo‐Ting Sun
      Journal of Cellular Biochemistry.2021; 122(11): 1749.     CrossRef
    • Curcuminoid (CRE-Ter)/Liposome as delivery platform for anti-osteoclastogenesis via NF-κB/ERK pathways in RANKL-induced RAW 264.7 cells through PLA foams
      Yutthana Pengjam, Pharkphoom Panichayupakaranant, Varaporn Tanrattanakul
      Heliyon.2021; 7(9): e07823.     CrossRef
    • Osteoblast lineage cells and periodontal ligament fibroblasts regulate orthodontic tooth movement that is dependent on Nuclear Factor-kappa B (NF-kB) activation
      Hyeran Helen Jeon, Chia-Ying Yang, Min Kyung Shin, Jingyi Wang, Juhin Hiren Patel, Chun-Hsi Chung, Dana T. Graves
      The Angle Orthodontist.2021; 91(5): 664.     CrossRef
    • Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
      Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
      Nature Communications.2021;[Epub]     CrossRef
    • Non-polar lipid from greenshell mussel (Perna canaliculus) inhibits osteoclast differentiation
      Parkpoom Siriarchavatana, Marlena C. Kruger, Matthew R. Miller, Hong Tian, Frances M. Wolber
      Bone Reports.2021; 15: 101132.     CrossRef
    • The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects
      Wenhao Lu, Wenfeng Xiao, Wenqing Xie, Xin Fu, Linyuan Pan, Hongfu Jin, Yongle Yu, Yi Zhang, Yusheng Li
      Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
    • IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling
      Inyoung Kim, Jung Ha Kim, Kabsun Kim, Semun Seong, Keun-Bae Lee, Nacksung Kim
      BMB Reports.2021; 54(9): 482.     CrossRef
    • Nanovibrational stimulation inhibits osteoclastogenesis and enhances osteogenesis in co-cultures
      John W. Kennedy, P. Monica Tsimbouri, Paul Campsie, Shatakshi Sood, Peter G. Childs, Stuart Reid, Peter S. Young, Dominic R. M. Meek, Carl S. Goodyear, Matthew J. Dalby
      Scientific Reports.2021;[Epub]     CrossRef
    • Propionibacterium freudenreichii Inhibits RANKL-Induced Osteoclast Differentiation and Ameliorates Rheumatoid Arthritis in Collagen-Induced Arthritis Mice
      Jiah Yeom, Dong Joon Yim, Seongho Ma, Young-Hee Lim
      Microorganisms.2021; 10(1): 48.     CrossRef
    • Identification of Critical Functional Modules and Signaling Pathways in Osteoporosis
      Xiaowei Jiang, Pu Ying, Yingchao Shen, Yiming Miu, Wenbin Kong, Tong Lu, Qiang Wang
      Current Bioinformatics.2021; 16(1): 90.     CrossRef
    • Osteogenic and Anti-Osteoclastogenic Properties of the Curcuminoid, CRE-Bin: Ex Vivo Experiments
      Jakkapong Inchai, Amornkan Numit, Suticha Chunta, Piyawut Swangphon, Pharkphoom Panichayupakaranant, Yutthana Pengjam
      SSRN Electronic Journal .2021;[Epub]     CrossRef
    • Biological and structural effects after intraosseous infiltrations of age‐dependent platelet‐rich plasma: An in vivo study
      Diego Delgado, Ane Garate, Pello Sánchez, Ane Miren Bilbao, Gontzal García del Caño, Joan Salles, Mikel Sánchez
      Journal of Orthopaedic Research.2020; 38(9): 1931.     CrossRef
    • Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice
      Dounia Hamoudi, Zineb Bouredji, Laetitia Marcadet, Hideo Yagita, Louis-Bénédict Landry, Anteneh Argaw, Jérôme Frenette
      Human Molecular Genetics.2020; 29(3): 483.     CrossRef
    • The Loss of Profilin 1 Causes Early Onset Paget's Disease of Bone
      Federica Scotto di Carlo, Laura Pazzaglia, Teresa Esposito, Fernando Gianfrancesco
      Journal of Bone and Mineral Research.2020; 35(8): 1387.     CrossRef
    • Characterization of Dysregulated lncRNA-Associated ceRNA Network Reveals Novel lncRNAs With ceRNA Activity as Epigenetic Diagnostic Biomarkers for Osteoporosis Risk
      Meijie Zhang, Luyang Cheng, Yina Zhang
      Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
    • Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System
      Christian Guder, Sascha Gravius, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg
      Frontiers in Immunology.2020;[Epub]     CrossRef
    • Multifactorial effects of hyperglycaemia, hyperinsulinemia and inflammation on bone remodelling in type 2 diabetes mellitus
      V.A. Shahen, M. Gerbaix, S. Koeppenkastrop, S.F. Lim, K.E. McFarlane, Amanda N.L. Nguyen, X.Y. Peng, N.B. Weiss, T.C. Brennan-Speranza
      Cytokine & Growth Factor Reviews.2020; 55: 109.     CrossRef
    • The Role of Ca2+-NFATc1 Signaling and Its Modulation on Osteoclastogenesis
      Jung Yun Kang, Namju Kang, Yu-Mi Yang, Jeong Hee Hong, Dong Min Shin
      International Journal of Molecular Sciences.2020; 21(10): 3646.     CrossRef
    • The Inhibition of Inflammatory Signaling Pathway by Secretory Leukocyte Protease Inhibitor can Improve Spinal Cord Injury
      Renzhe Tang, Benson O. A. Botchway, Yanfeng Meng, Yong Zhang, Conghui Zhou, Junsong Jiang, Xuehong Liu
      Cellular and Molecular Neurobiology.2020; 40(7): 1067.     CrossRef
    • Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone
      Elizabeth Stephens, Michèle Roy, Martine Bisson, Hoang Dong Nguyen, Michelle S. Scott, Gilles Boire, Luigi Bouchard, Sophie Roux
      Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2020; 1866(10): 165852.     CrossRef
    • Osteoimmunomodulatory effects of biomaterial modification strategies on macrophage polarization and bone regeneration
      Yajuan Xie, Cheng Hu, Yi Feng, Danfeng Li, Tingting Ai, Yulei Huang, Xiaodan Chen, Lijia Huang, Jiali Tan
      Regenerative Biomaterials.2020; 7(3): 233.     CrossRef
    • A review of the latest insights into the mechanism of action of strontium in bone
      Daniella Marx, Alireza Rahimnejad Yazdi, Marcello Papini, Mark Towler
      Bone Reports.2020; 12: 100273.     CrossRef
    • Regulatory network mediated by RBP‐J/NFATc1‐miR182 controls inflammatory bone resorption
      Kazuki Inoue, Xiaoyu Hu, Baohong Zhao
      The FASEB Journal.2020; 34(2): 2392.     CrossRef
    • Cedrol attenuates collagen-induced arthritis in mice and modulates the inflammatory response in LPS-mediated fibroblast-like synoviocytes
      Xue Chen, Jian Shen, Jun-ming Zhao, Jian Guan, Wei Li, Qiang-min Xie, Yu-qing Zhao
      Food & Function.2020; 11(5): 4752.     CrossRef
    • Tablysin-15 inhibits osteoclastogenesis and LPS-induced bone loss via attenuating the integrin αvβ3 pathway
      Qingye Zeng, Wancheng Lu, Zhenhui Deng, Jiena Wu, Ruiyin Guo, Xueqing Xu
      Chemico-Biological Interactions.2020; 327: 109179.     CrossRef
    • The role of cytokines in bone remodeling and the pathogenesis of postmenopausal osteoporosis
      G. A. Ignatenko, I. G. Nemsadze, E. D. Mirovich, A. V. Churilov, E. A. Maylyan, I. S. Glazkov, Z. S. Rumyantceva
      Medical Herald of the South of Russia.2020; 11(2): 6.     CrossRef
    • Effect of echinalkamide identified from Echinacea purpurea (L.) Moench on the inhibition of osteoclastogenesis and bone resorption
      Bo Yoon Chang, Seul Ki Lee, Da Eun Kim, Jin Hye Bae, Thanh Tam Ho, So-Young Park, Mi Kyeong Lee, Sung Yeon Kim
      Scientific Reports.2020;[Epub]     CrossRef
    • A Synthetic Peptide, CK2.3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway
      John Nguyen, Semaj Kelly, Ryan Wood, Brian Heubel, Anja Nohe
      Journal of Developmental Biology.2020; 8(3): 12.     CrossRef
    • Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
      Jiyong Wei, Yicheng Li, Qian Liu, Yanni Lan, Chengming Wei, Kun Tian, Liwei Wu, Chunbo Lin, Jiake Xu, Jinmin Zhao, Yuan Yang
      Frontiers in Pharmacology.2020;[Epub]     CrossRef
    • Polyphenols from grape pomace induce osteogenic differentiation in mesenchymal stem cells
      Elisa Torre, Giorgio Iviglia, Clara Cassinelli, Marco Morra, Nazario Russo
      International Journal of Molecular Medicine.2020;[Epub]     CrossRef
    • Mathematical modeling of canonical and non-canonical NF-κB pathways in TNF stimulation
      Bing Ji, Yao Zhang, Changqing Zhen, Michael J Fagan, Qing Yang
      Computer Methods and Programs in Biomedicine.2020; 196: 105677.     CrossRef
    • Collagen VIα2 chain deficiency causes trabecular bone loss by potentially promoting osteoclast differentiation through enhanced TNFα signaling
      Hai T. Pham, Vardit Kram, Qurratul-Ain Dar, Taishi Komori, Youngmi Ji, Payam Mohassel, Jachinta Rooney, Li Li, Tina M. Kilts, Carsten Bonnemann, Shireen Lamande, Marian F. Young
      Scientific Reports.2020;[Epub]     CrossRef
    • Medicinal plants used against various inflammatory biomarkers for the management of rheumatoid arthritis
      Shareen Singh, Thakur Gurjeet Singh, Kriti Mahajan, Sonia Dhiman
      Journal of Pharmacy and Pharmacology.2020; 72(10): 1306.     CrossRef
    • The regulatory role of the RANKL/RANK/OPG signaling pathway in the mechanisms of tooth eruption in patients with impacted teeth
      Ludmila Brodetska, Larysa Natrus, Olha Lisakovska, Olexandr Kaniura, Liudmyla Iakovenko, Irina Skrypnyk, Petro Flis
      BMC Oral Health.2020;[Epub]     CrossRef
    • Activation of Nell-1 in BMSC Sheet Promotes Implant Osseointegration Through Regulating Runx2/Osterix Axis
      Kaichen Lai, Yue Xi, Xue Du, Zhiwei Jiang, Yongzheng Li, Tingben Huang, Xiaoyan Miao, Huiming Wang, Ying Wang, Guoli Yang
      Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
    • Epigenetic Regulators Involved in Osteoclast Differentiation
      Kristina Astleford, Emily Campbell, Andrew Norton, Kim C. Mansky
      International Journal of Molecular Sciences.2020; 21(19): 7080.     CrossRef
    • NIK inhibitor impairs chronic periodontitis via suppressing non-canonical NF-κB and osteoclastogenesis
      Jiang Wang, Bo Wang, Xin Lv, Lei Wang
      Pathogens and Disease.2020;[Epub]     CrossRef
    • Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases
      Bettina Sehnert, Harald Burkhardt, Stefan Dübel, Reinhard E. Voll
      Cells.2020; 9(7): 1627.     CrossRef
    • Intrinsic Restriction of TNF-Mediated Inflammatory Osteoclastogenesis and Bone Resorption
      Baohong Zhao
      Frontiers in Endocrinology.2020;[Epub]     CrossRef
    • Grape Seed Proanthocyanidin Extract Prevents Bone Loss via Regulation of Osteoclast Differentiation, Apoptosis, and Proliferation
      Sung Chul Kwak, Yoon-Hee Cheon, Chang Hoon Lee, Hong Young Jun, Kwon-Ha Yoon, Myeung Su Lee, Ju-Young Kim
      Nutrients.2020; 12(10): 3164.     CrossRef
    • Relationship Between Metabolic Syndrome and Bone Health – An Evaluation of Epidemiological Studies and Mechanisms Involved


      Kok-Yong Chin, Sok Kuan Wong, Sophia Ogechi Ekeuku, Kok-Lun Pang
      Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3667.     CrossRef
    • The Beneficial Effect of Boswellic Acid on Bone Metabolism and Possible Mechanisms of Action in Experimental Osteoporosis
      Bandar E. Al-Dhubiab, Snehal S. Patel, Mohamed A. Morsy, Harika Duvva, Anroop B. Nair, Pran Kishore Deb, Jigar Shah
      Nutrients.2020; 12(10): 3186.     CrossRef
    • Inhibition of Osteoclast Differentiation by Carotenoid Derivatives through Inhibition of the NF-κB Pathway
      Shlomit Odes-Barth, Marina Khanin, Karin Linnewiel-Hermoni, Yifat Miller, Karina Abramov, Joseph Levy, Yoav Sharoni
      Antioxidants.2020; 9(11): 1167.     CrossRef
    • Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
      Xin Zhi, Qian Chen, Shaojun Song, Zhengrong Gu, Wenqiang Wei, Huiwen Chen, Xiao Chen, Weizong Weng, Qirong Zhou, Jin Cui, Liehu Cao
      Frontiers in Pharmacology.2020;[Epub]     CrossRef
    • Noncanonical NF-κB Signaling Pathway in Liver Diseases
      Qianhui Chen, Xinyu Lu, Xiaoyong Zhang
      Journal of Clinical and Translational Hepatology.2020; 000(000): 1.     CrossRef
    • Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL
      David H.H. Molstad, Anna M. Mattson, Dana L. Begun, Jennifer J. Westendorf, Elizabeth W. Bradley
      Journal of Biological Chemistry.2020; 295(51): 17713.     CrossRef
    • Insertion Mutation in Tnfrsf11a Causes a Paget's Disease–Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice
      Nerea Alonso, Sachin Wani, Lorraine Rose, Rob J. van't Hof, Stuart H. Ralston, Omar M.E. Albagha
      Journal of Bone and Mineral Research.2020; 36(7): 1376.     CrossRef
    • Rictor Is a Novel Regulator of TRAF6/TRAF3 in Osteoclasts
      Song Xu, Shihai Li, Xianming Liu, Kang Tan, Jiahuan Zhang, Kai Li, Xiaochun Bai, Yue Zhang
      Journal of Bone and Mineral Research.2020; 36(10): 2053.     CrossRef
    • KLF2 (kruppel-like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy
      Dipranjan Laha, Moonmoon Deb, Hiranmoy Das
      Autophagy.2019; 15(12): 2063.     CrossRef
    • Dissecting the Role of NF-κb Protein Family and Its Regulators in Rheumatoid Arthritis Using Weighted Gene Co-Expression Network
      Jamal S. M. Sabir, Abdelfatteh El Omri, Babajan Banaganapalli, Majed A. Al-Shaeri, Naser A. Alkenani, Mumdooh J. Sabir, Nahid H. Hajrah, Houda Zrelli, Lukasz Ciesla, Khalidah K. Nasser, Ramu Elango, Noor Ahmad Shaik, Muhummadh Khan
      Frontiers in Genetics.2019;[Epub]     CrossRef
    • Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation
      Yong Xie, Licheng Zhang, Qi Xiong, Yanpan Gao, Wei Ge, Peifu Tang
      Bone Research.2019;[Epub]     CrossRef
    • Platelet‐rich fibrin/biphasic calcium phosphate impairs osteoclast differentiation and promotes apoptosis by the intrinsic mitochondrial pathway in chronic periodontitis
      Anil Kumar, Jaideep Mahendra, Shila Samuel, Jayamathi Govindraj, Tholcopiyan Loganathan, Yaongamphi Vashum, Little Mahendra, Thiagarajan Krishnamoorthy
      Journal of Periodontology.2019; 90(1): 61.     CrossRef
    • Cyclin‐dependent kinase 8/19 inhibition suppresses osteoclastogenesis by downregulating RANK and promotes osteoblast mineralization and cancellous bone healing
      Mehdi Amirhosseini, Magnus Bernhardsson, Pernilla Lång, Göran Andersson, Johan Flygare, Anna Fahlgren
      Journal of Cellular Physiology.2019; 234(9): 16503.     CrossRef
    • Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice
      Hannah M. Davis, Alyson L. Essex, Sinai Valdez, Padmini J. Deosthale, Mohammad W. Aref, Matthew R. Allen, Andrea Bonetto, Lilian I. Plotkin
      Bone.2019; 124: 89.     CrossRef
    • Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women
      Olfat G. Shaker, Mahmoud A. Senousy
      Clinical Breast Cancer.2019; 19(1): e220.     CrossRef
    • Sialoglycoproteins Isolated from the Eggs of Gadus morhua Inhibit Bone Resorption in Ovariectomized Rats by Suppressing the MAPK and NF-κB Pathways
      Lei Mao, Yiming Wang, Meiling Wang, Yufeng Dai, Jingfeng Wang, Changhu Xue
      Journal of Ocean University of China.2019; 18(5): 1174.     CrossRef
    • Mathematical modelling of bone remodelling cycles including the NFκB signalling pathway
      Bing Ji, Yao Zhang, Changqing Zhen, Michael J. Fagan, Qing Yang
      Computers in Biology and Medicine.2019; 107: 257.     CrossRef
    • Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
      Haiming Jin, Qingqing Wang, Kai Chen, Ke Xu, Hao Pan, Feifan Chu, Zhen Ye, Ziyi Wang, Jennifer Tickner, Heng Qiu, Chao Wang, Jacob Kenny, Huazi Xu, Te Wang, Jiake Xu
      Journal of Cellular and Molecular Medicine.2019; 23(12): 8355.     CrossRef
    • Regulation of Osteoclast Differentiation and Skeletal Maintenance by Histone Deacetylases
      Bora Faulkner, Kristina Astleford, Kim Mansky
      Molecules.2019; 24(7): 1355.     CrossRef
    • Benzylideneacetone Derivatives Inhibit Osteoclastogenesis and Activate Osteoblastogenesis Independently Based on Specific Structure–Activity Relationship
      Triveni Pativada, Myung Hwan Kim, Jung-Hun Lee, Seong Su Hong, Chun Whan Choi, Yun-Hyeok Choi, Woo Jung Kim, Da-Woon Song, Serk In Park, Eun Jung Lee, Bo-Yeon Seo, Hankyeom Kim, Hong Kyu Kim, Kee Ho Lee, Sung K. Ahn, Jin-Mo Ku, Gil Hong Park
      Journal of Medicinal Chemistry.2019; 62(13): 6063.     CrossRef
    • The Coumarin Derivative 5′-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways
      Basem M. Abdallah, Enas M. Ali, Hany Elsawy, Gehan M. Badr, Ashraf M. Abdel-Moneim, Abdullah M. Alzahrani
      BioMed Research International.2019; 2019: 1.     CrossRef
    • Characterizing how probiotic Lactobacillus reuteri 6475 and lactobacillic acid mediate suppression of osteoclast differentiation
      Darin Quach, Narayanan Parameswaran, Laura McCabe, Robert A. Britton
      Bone Reports.2019; 11: 100227.     CrossRef
    • RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
      Jooyeon Jhun, Seung Hoon Lee, Se-Young Kim, Jaeyoon Ryu, Ji Ye Kwon, Hyun Sik Na, KyoungAh Jung, Su-Jin Moon, Mi-La Cho, Jun-Ki Min
      Journal of Translational Medicine.2019;[Epub]     CrossRef
    • The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation
      Inyoung Kim, Jung Ha Kim, Kabsun Kim, Semun Seong, Nacksung Kim
      BMB Reports.2019; 52(7): 469.     CrossRef
    • Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS‐stimulated co‐cultures of periodontal ligament and RAW 264.7 cells, and RANKL‐mediated osteoclastogenesis and bone resorption in PBMCs
      Anna Kats, Natalija Gerasimcik, Tuomas Näreoja, Jonas Nederberg, Simon Grenlöv, Ekaterina Lagnöhed, Suchita Desai, Göran Andersson, Tülay Yucel‐Lindberg
      Journal of Cellular and Molecular Medicine.2019; 23(2): 1152.     CrossRef
    • Regulator of G protein signaling 12 enhances osteoclastogenesis by suppressing Nrf2-dependent antioxidant proteins to promote the generation of reactive oxygen species
      Andrew Ying Hui Ng, Ziqing Li, Megan M Jones, Shuting Yang, Chunyi Li, Chuanyun Fu, Chengjian Tu, Merry Jo Oursler, Jun Qu, Shuying Yang
      eLife.2019;[Epub]     CrossRef
    • Molecular mechanisms linking peri-implantitis and type 2 diabetes mellitus revealed by transcriptomic analysis
      Tianliang Yu, Aneesha Acharya, Nikos Mattheos, Simin Li, Dirk Ziebolz, Gerhard Schmalz, Rainer Haak, Jana Schmidt, Yu Sun
      PeerJ.2019; 7: e7124.     CrossRef
    • Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
      Qingqing Wang, Lingya Yao, Ke Xu, Haiming Jin, Kai Chen, Ziyi Wang, Qian Liu, Zhen Cao, Jacob kenny, Yuhao Liu, Jennifer Tickner, Huazi Xu, Jiake Xu
      Journal of Cellular and Molecular Medicine.2019; 23(1): 380.     CrossRef
    • Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo
      Silvia Marino, Ryan T. Bishop, Giovana Carrasco, John G. Logan, Boya Li, Aymen I. Idris
      Calcified Tissue International.2019; 105(2): 193.     CrossRef
    • TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis
      Jinbo Li, Akram Ayoub, Yan Xiu, Xiaoxiang Yin, James O. Sanders, Addisu Mesfin, Lianping Xing, Zhenqiang Yao, Brendan F. Boyce
      Nature Communications.2019;[Epub]     CrossRef
    • A simple and robust reporter gene assay for measuring the bioactivity of anti-RANKL therapeutic antibodies
      Chuanfei Yu, Lan Wang, Yongbo Ni, Junzhi Wang
      RSC Advances.2019; 9(69): 40196.     CrossRef
    • Tatarinan T, an α‐asarone‐derived lignin, attenuates osteoclastogenesis induced by RANKL via the inhibition of NFATc1/c‐Fos expression
      Yuxin Zhang, Zhi Wang, Xiaona Xie, Shaoming Wang, Yingjian Wang, Guihua Quan, Hongbing Wang, Wan‐chun Sun
      Cell Biology International.2019; 43(12): 1471.     CrossRef
    • The Effect of Curcumin on the Differentiation of Mesenchymal Stem Cells into Mesodermal Lineage
      Armita Mahdavi Gorabi, Nasim Kiaie, Saeideh Hajighasemi, Tannaz Jamialahmadi, Muhammed Majeed, Amirhossein Sahebkar
      Molecules.2019; 24(22): 4029.     CrossRef
    • Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases
      Taiwo Samuel Agidigbi, Chaekyun Kim
      International Journal of Molecular Sciences.2019; 20(14): 3576.     CrossRef
    • Identification of anti-inflammatory components in Sinomenii Caulis based on spectrum-effect relationship and chemometric methods
      Lan-Jin Wang, Zheng-Meng Jiang, Ping-Ting Xiao, Jian-Bo Sun, Zhi-Ming Bi, E-Hu Liu
      Journal of Pharmaceutical and Biomedical Analysis.2019; 167: 38.     CrossRef
    • I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma
      Ning-Hong Guo, Ji-Fu Zheng, Fu-Ming Zi, Jing Cheng
      Bioscience Reports.2019;[Epub]     CrossRef
    • The polyadenylation inhibitor cordycepin reduces pain, inflammation and joint pathology in rodent models of osteoarthritis
      Sadaf Ashraf, Masar Radhi, Peter Gowler, James J. Burston, Raj D. Gandhi, Graeme J. Thorn, Anna M. Piccinini, David A. Walsh, Victoria Chapman, Cornelia H. de Moor
      Scientific Reports.2019;[Epub]     CrossRef
    • An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice
      Dounia Hamoudi, Laetitia Marcadet, Antoine Piette Boulanger, Hideo Yagita, Zineb Bouredji, Anteneh Argaw, Jérôme Frenette
      Human Molecular Genetics.2019; 28(18): 3101.     CrossRef
    • Dual-Purpose Magnesium-Incorporated Titanium Nanotubes for Combating Bacterial Infection and Ameliorating Osteolysis to Realize Better Osseointegration
      Ying Yang, Lihong Liu, Hang Luo, Dou Zhang, Shaorong Lei, Kechao Zhou
      ACS Biomaterials Science & Engineering.2019; 5(10): 5368.     CrossRef
    • Inhibition of Osteoclastogenesis by Thioredoxin-Interacting Protein-Derived Peptide (TN13)
      Mi Kim, Won Kim, Jae-Eun Byun, Jung Choi, Suk Yoon, Inpyo Choi, Haiyoung Jung
      Journal of Clinical Medicine.2019; 8(4): 431.     CrossRef
    • Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model
      Chulwon Kim, Jong Hyun Lee, Jeong-Hyeon Ko, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Omar H.M. Shair, Gautam Sethi, Kwang Seok Ahn
      Biomolecules.2019; 9(7): 262.     CrossRef
    • Longan fruit increase bone mineral density in zebrafish and ovariectomized rat by suppressing RANKL-induced osteoclast differentiation
      Younglim Son, Eun Mi Lee, Do Yup Lee, Jong Hun Lee, Sangtaek Oh
      Phytomedicine.2019; 59: 152910.     CrossRef
    • From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights
      Anesi, Generali, Sandoni, Pozzi, Grande
      International Journal of Molecular Sciences.2019; 20(19): 4925.     CrossRef
    • Tetrandrine attenuates the bone erosion in collagen‐induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase
      Yugai Jia, Yumeng Miao, Mengfan Yue, Mei Shu, Zhifeng Wei, Yue Dai
      The FASEB Journal.2018; 32(6): 3398.     CrossRef
    • Bone turnover markers and novel biomarkers in lung cancer bone metastases
      Jiangli Lang, Qian Zhao, Yuedong He, Xijie Yu
      Biomarkers.2018; 23(6): 518.     CrossRef
    • Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
      Zi’ang Hu, Yilei Chen, Lijiang Song, Jasper H. N. Yik, Dominik R. Haudenschild, Shunwu Fan
      Frontiers in Pharmacology.2018;[Epub]     CrossRef
    • PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
      Joo-Hee Choi, Ah-Ra Jang, Dong-il Kim, Min-Jung Park, Seul-Ki Lim, Myung-Sun Kim, Jong-Hwan Park
      Experimental & Molecular Medicine.2018; 50(8): 1.     CrossRef
    • Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL‐induced NFAT activation and calcium signaling
      Chuan Liu, Zhen Cao, Wen Zhang, Jennifer Tickner, Heng Qiu, Chao Wang, Kai Chen, Ziyi Wang, Renxiang Tan, Shiwu Dong, Jiake Xu
      Journal of Cellular Physiology.2018; 233(11): 8971.     CrossRef
    • Shared epitope–aryl hydrocarbon receptor crosstalk underlies the mechanism of gene–environment interaction in autoimmune arthritis
      Jiaqi Fu, Sarah V. Nogueira, Vincent van Drongelen, Patrick Coit, Song Ling, Edward F. Rosloniec, Amr H. Sawalha, Joseph Holoshitz
      Proceedings of the National Academy of Sciences.2018; 115(18): 4755.     CrossRef
    • LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-κB and p38 Pathways During Osteoclastogenesis
      Di Lu, Jianshuang Li, Huadie Liu, Gabrielle E Foxa, Kevin Weaver, Jie Li, Bart O Williams, Tao Yang
      Journal of Bone and Mineral Research.2018; 33(10): 1773.     CrossRef
    • Effects of Vitamin D on Skeletal Muscle and Athletic Performance
      Geoffrey D. Abrams, David Feldman, Marc R. Safran
      Journal of the American Academy of Orthopaedic Surgeons.2018; 26(8): 278.     CrossRef
    • TRIM38 regulates NF-κB activation through TAB2 degradation in osteoclast and osteoblast differentiation
      Kabsun Kim, Jung Ha Kim, Inyoung Kim, Semun Seong, Nacksung Kim
      Bone.2018; 113: 17.     CrossRef
    • Isosteviol Derivative Inhibits Osteoclast Differentiation and Ameliorates Ovariectomy-Induced Osteoporosis
      Huey-En Tzeng, Po-Hao Huang, Chun-Hao Tsai, Gregory J Tsay, Yi-Ju Lee, Tsurng-Juhn Huang, Tzu-Hung Lin, Ying-Ming Chiu, Yi-Ying Wu
      Scientific Reports.2018;[Epub]     CrossRef
    • 3′‐Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis
      Li‐Jung Kang, Eun‐Soo Kwon, Kwang Min Lee, Chanmi Cho, Jae‐In Lee, Young Bae Ryu, Tae Hyun Youm, Jimin Jeon, Mi Ra Cho, Seon‐Yong Jeong, Sang‐Rae Lee, Wook Kim, Siyoung Yang
      British Journal of Pharmacology.2018; 175(23): 4295.     CrossRef
    • Mepazine Inhibits RANK-Induced Osteoclastogenesis Independent of Its MALT1 Inhibitory Function
      Laura Meloni, Lynn Verstrepen, Marja Kreike, Jens Staal, Yasmine Driege, Inna Afonina, Rudi Beyaert
      Molecules.2018; 23(12): 3144.     CrossRef
    • Activated protein C suppresses osteoclast differentiation via endothelial protein C receptor, protease-activated receptor-1, sphingosine 1-phosphate receptor, and apolipoprotein E receptor 2
      Kakunoshin Yoshida, Nobuyuki Akita, Takayuki Okamoto, Kunihiro Asanuma, Atsumasa Uchida, Akihiro Sudo, Motomu Shimaoka, Koji Suzuki, Tatsuya Hayashi
      Thrombosis Research.2018; 163: 30.     CrossRef
    • Dietary nutraceuticals as backbone for bone health
      Manoj K. Pandey, Subash C. Gupta, Deepkamal Karelia, Patrick J. Gilhooley, Mehdi Shakibaei, Bharat B. Aggarwal
      Biotechnology Advances.2018; 36(6): 1633.     CrossRef
    • Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells
      Yaxian Ma, Xiaoyong Qiao, Rujun Zeng, Ran Cheng, Jun Zhang, Yunyao Luo, Ying Nie, Ying Hu, Zhilan Yang, Jing Zhang, Lin Liu, Wenming Xu, Charles C. Xu, Liangzhi Xu
      The FASEB Journal.2018; 32(11): 5813.     CrossRef
    • Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets
      Andrew Paul, Joanne Edwards, Christopher Pepper, Simon Mackay
      Cells.2018; 7(10): 176.     CrossRef
    • Rooibos tea extracts inhibit osteoclast formation and activity through the attenuation of NF-κB activity in RAW264.7 murine macrophages
      Shaakirah Moosa, Abe E. Kasonga, Vishwa Deepak, Sumari Marais, Innocentia B. Magoshi, Megan J. Bester, Marlena C. Kruger, Magdalena Coetzee
      Food & Function.2018; 9(6): 3301.     CrossRef
    • Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway
      Hari Madhuri Doss, Snigdha Samarpita, Ramamoorthi Ganesan, Mahaboobkhan Rasool
      Life Sciences.2018; 207: 284.     CrossRef
    • Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways
      Fangqing Chen, Lin Xie, Ran Kang, Rongrong Deng, Zhipeng Xi, Daoxi Sun, Jin Zhu, Liming Wang
      Biomedicine & Pharmacotherapy.2018; 100: 142.     CrossRef
    • Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation
      Qiang Zhang, Xinqiao Tang, Zhong Liu, Xiaoxia Song, Dan Peng, Wei Zhu, Zhengxiao Ouyang, Wanchun Wang
      Frontiers in Pharmacology.2018;[Epub]     CrossRef
    • Anemarrhena�asphodeloides Bunge ameliorates osteoporosis by suppressing osteoclastogenesis
      Jae Lee, Mi Kim, Haesu Lee, Woong Yang
      International Journal of Molecular Medicine.2018;[Epub]     CrossRef
    • RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors
      Zhenqiang Yao, Wei Lei, Rong Duan, Yanyun Li, Lu Luo, Brendan F. Boyce
      Journal of Biological Chemistry.2017; 292(24): 10169.     CrossRef
    • The Alpha 7 Nicotinic Acetylcholine Receptor of Deciduous Dental Pulp Stem Cells Regulates Osteoclastogenesis During Physiological Root Resorption
      Lulu Wang, Zhifei Zhou, Yujiang Chen, Shuai Yuan, Yang Du, Xinke Ju, Lizheng Wu, Xiaojing Wang
      Stem Cells and Development.2017; 26(16): 1186.     CrossRef
    • Unexpected Bone Formation Produced by RANKL Blockade
      Sergio Portal-Núñez, Aranzazu Mediero, Pedro Esbrit, Olga Sánchez-Pernaute, Raquel Largo, Gabriel Herrero-Beaumont
      Trends in Endocrinology & Metabolism.2017; 28(10): 695.     CrossRef
    • Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption
      Nikolaus Binder, Christine Miller, Masaki Yoshida, Kazuki Inoue, Shinichi Nakano, Xiaoyu Hu, Lionel B. Ivashkiv, Georg Schett, Alessandra Pernis, Steven R. Goldring, F. Patrick Ross, Baohong Zhao
      The Journal of Immunology.2017; 198(9): 3436.     CrossRef
    • Suppression of Osteoclastogenesis by Melatonin: A Melatonin Receptor-Independent Action
      Hyung Kim, Ha Kim, Moon-Kyoung Bae, Yong-Deok Kim
      International Journal of Molecular Sciences.2017; 18(6): 1142.     CrossRef
    • The effects of downhill and uphill exercise training on osteogenesis-related factors in ovariectomy-induced bone loss
      Yun-Seok Kang, Chun-Ho Kim, Jeong-Seok Kim
      Journal of Exercise Nutrition & Biochemistry.2017; 21(3): 1.     CrossRef
    • Small leucine rich proteoglycans, a novel link to osteoclastogenesis
      Vardit Kram, Tina M. Kilts, Nisan Bhattacharyya, Li Li, Marian F. Young
      Scientific Reports.2017;[Epub]     CrossRef
    • Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity
      Libo Zhao, Cong Cai, Jing Wang, Liming Zhao, Weijin Li, Changyu Liu, Hanfeng Guan, Yuanli Zhu, Jun Xiao
      Frontiers in Pharmacology.2017;[Epub]     CrossRef
    • MicroRNAs and Periodontal Homeostasis
      X. Luan, X. Zhou, J. Trombetta-eSilva, M. Francis, A.K. Gaharwar, P. Atsawasuwan, T.G.H. Diekwisch
      Journal of Dental Research.2017; 96(5): 491.     CrossRef
    • Hypoxia‐inducible factor 1‐alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl‐4‐hydroxylase 2
      Philippa A Hulley, Tammie Bishop, Aude Vernet, Jurgen E Schneider, James R Edwards, Nick A Athanasou, Helen J Knowles
      The Journal of Pathology.2017; 242(3): 322.     CrossRef
    • mTORC1 Inhibits NF-κB/NFATc1 Signaling and Prevents Osteoclast Precursor Differentiation, In Vitro and In Mice
      Yue Zhang, Song Xu, Kai Li, Kang Tan, Kangyan Liang, Jian Wang, Junhui Shen, Wenchong Zou, Le Hu, Daozhang Cai, Changhai Ding, Mangmang Li, Guozhi Xiao, Bin Liu, Anling Liu, Xiaochun Bai
      Journal of Bone and Mineral Research.2017; 32(9): 1829.     CrossRef
    • Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair
      Rachel N. Frisch, Kevin M. Curtis, Kristina K. Aenlle, Guy A. Howard
      Expert Opinion on Therapeutic Targets.2016; 20(9): 1087.     CrossRef
    • CCAAT/Enhancer-binding Protein α (C/EBPα) Is Important for Osteoclast Differentiation and Activity
      Joel Jules, Wei Chen, Xu Feng, Yi-Ping Li
      Journal of Biological Chemistry.2016; 291(31): 16390.     CrossRef
    • Ginsenoside Re Inhibits Osteoclast Differentiation in Mouse Bone Marrow-Derived Macrophages and Zebrafish Scale Model
      Chan-Mi Park, Hye-Min Kim, Dong Hyun Kim, Ho-Jin Han, Haneul Noh, Jae-Hyuk Jang, Soo-Hyun Park, Han-Jung Chae, Soo-Wan Chae, Eun Kyoung Ryu, Sangku Lee, Kangdong Liu, Haidan Liu, Jong-Seog Ahn, Young Ock Kim, Bo-Yeon Kim, Nak-Kyun Soung
      Molecules and Cells.2016; 39(12): 855.     CrossRef
    • RBP-J–Regulated miR-182 Promotes TNF-α–Induced Osteoclastogenesis
      Christine H. Miller, Sinead M. Smith, Mahmoud Elguindy, Tuo Zhang, Jenny Z. Xiang, Xiaoyu Hu, Lionel B. Ivashkiv, Baohong Zhao
      The Journal of Immunology.2016; 196(12): 4977.     CrossRef
    • Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation
      Wei Ming, Gan Lu, Sha Xin, Lu Huanyu, Jiang Yinghao, Lei Xiaoying, Xu Chengming, Ruan Banjun, Wang Li, Lu Zifan
      Biochemical and Biophysical Research Communications.2016; 476(4): 412.     CrossRef
    • Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis
      Daniele Bellavia, Viviana Costa, Angela De Luca, Melania Maglio, Stefania Pagani, Milena Fini, Gianluca Giavaresi
      Current Osteoporosis Reports.2016;[Epub]     CrossRef
    • Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway
      Supatta Chawalitpong, Nilubon Sornkaew, Apichart Suksamrarn, Tanapat Palaga
      European Journal of Pharmacology.2016; 788: 351.     CrossRef
    • NF‐κB acts as a multifunctional modulator in bone invasion by oral squamous cell carcinoma
      Eijiro Jimi, Shoichiro Kokabu, Takuma Matsubara, Chihiro Nakatomi, Kou Matsuo, Seiji Watanabe
      Oral Science International.2016; 13(1): 1.     CrossRef
    • DLX3 negatively regulates osteoclastic differentiation through microRNA-124
      Na Zhao, Dong Han, Yang Liu, Yue Li, Li Zeng, Yixiang Wang, Hailan Feng
      Experimental Cell Research.2016; 341(2): 166.     CrossRef
    • Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender
      Eliana Pivetta, Bruna Wassermann, Pietro Bulian, Agostino Steffan, Alfonso Colombatti, Jerry Polesel, Paola Spessotto
      Oncotarget.2015; 6(31): 31889.     CrossRef
    • The Multiple Roles of Microrna-223 in Regulating Bone Metabolism
      Yong Xie, Lihai Zhang, Yanpan Gao, Wei Ge, Peifu Tang
      Molecules.2015; 20(10): 19433.     CrossRef
    • Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways
      Tao Wang, Qian Liu, Lin Zhou, Jin Yuan, Xixi Lin, Rong Zeng, Xiaonan Liang, Jinmin Zhao, Jiake Xu
      International Journal of Molecular Sciences.2015; 16(11): 27470.     CrossRef
    • Molecular and epigenetic basis of macrophage polarized activation
      Chiara Porta, Elena Riboldi, Alessandro Ippolito, Antonio Sica
      Seminars in Immunology.2015; 27(4): 237.     CrossRef

    • PubReader PubReader
    • Cite
      CITE
      export Copy
      Close
    • XML DownloadXML Download
    Figure
    Related articles

    Endocrinol Metab : Endocrinology and Metabolism